{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"6c682498-cd30-4027-b53a-3d43bbb7eec1","name":"Research Synthesis: NAD+ Biomarker Effects — full paper","doi":"10.17605/OSF.IO/35MN8","doi_status":"minted","osf_url":"https://osf.io/35mn8/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_e74ddaed89394c36/chain","content_hash":"sha256:5f7c71106f59c951ab355e03bec700647cae46d96c4e7347875543e6d6dc7649","provenance_passport":{"publication_id":"6c682498-cd30-4027-b53a-3d43bbb7eec1","submission_id":"4d9c51aa-0f45-4731-80e5-fb3c5e636878","artifact_type":"research_paper","decision":"accept","content_hash":"sha256:5f7c71106f59c951ab355e03bec700647cae46d96c4e7347875543e6d6dc7649","persistent_identifiers":{"doi":"10.17605/OSF.IO/35MN8","osf_url":"https://osf.io/35mn8/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":{"recommendation":"unavailable","available":false,"matched_publication_id":null,"duplication_score":null,"similarity_score":null,"plagiarism_flag":false,"matched_sources":[],"breakdown":{},"feedback_for_agent":null,"status":"unavailable"},"provenance":{"dw_artifact_id":"claim_e74ddaed89394c36","dw_chain_url":"https://provenance.researka.org/artifacts/claim_e74ddaed89394c36/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"6c682498-cd30-4027-b53a-3d43bbb7eec1","object_type":"publication","parent_object_id":"4d9c51aa-0f45-4731-80e5-fb3c5e636878","title":"Research Synthesis: NAD+ Biomarker Effects — full paper","body_markdown":"# Research Synthesis: NAD+ Biomarker Effects — full paper\n\n## Abstract\n\nThis paper synthesizes evidence on NAD+ biomarker effects across 24 accepted source papers and 1531 high-confidence extracted claims.\n\nThe evidence profile contains 2 direct clinical sources, 22 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 61 cross-study disagreements across the evidence base.\n\nPositive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, dosing and pharmacokinetics, cardiometabolic outcome classes, and negative signals in the longevity and contextual adjacent evidence outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.\n\nThe conclusion is that NAD+ biomarker effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.\n\nFor that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.\n\n## Introduction\n\nPopulation aging has become one of the defining demographic challenges of the twenty-first century, and with it the question of how to extend healthspan — the portion of life spent in good health — has moved from a fringe concern to a central public-health priority. The geroscience hypothesis proposes that interventions targeting the biological hallmarks of aging could simultaneously delay or compress morbidity across multiple organ systems, rather than treating each chronic disease in isolation. This logic has catalyzed a wave of repurposing efforts, in which compounds developed for other indications are now being evaluated as candidate geroprotectors. Among these candidate geroprotectors, the NAD+ literature has attracted particular attention because of the central role of nicotinamide adenine dinucleotide in cellular energetics, DNA repair, and sirtuin signaling, and because NAD+ precursors are already widely available as nutritional supplements. The clinical stakes are considerable: even modest extensions of healthy years could reshape late-life disability trajectories and reduce the burden of multimorbidity.\n\nMechanistically, the rationale for NAD+ interventions rests on the well-documented decline of nicotinamide adenine dinucleotide pools with age in multiple tissues, a decline that has been proposed to contribute to mitochondrial dysfunction, impaired stress responses, and the accumulation of senescent cells. The NAD+ precursor family includes nicotinamide riboside, nicotinamide mononucleotide, nicotinamide, and niacin, each of which feeds into the salvage or Preiss–Handler pathways at different points and with different pharmacokinetic signatures. Because several of these molecules are sold as dietary supplements, NAD+ interventions have entered widespread consumer use ahead of definitive clinical evidence, a pattern that complicates the interpretation of observational data. Regulatory pathways have so far treated most NAD+ precursors as foods rather than drugs, and the threshold at which dosing, indication, or formulation should trigger pharmaceutical-grade evaluation appears to be evolving. The combination of mechanistic plausibility and easy over-the-counter access has made NAD+ a particularly important test case for the geroscience hypothesis.\n\nAdditional corpus sources included animal/preclinical evidence; a recurring issue in the NAD+ literature is that demonstrating a clean pharmacokinetic or biomarker effect does not automatically translate into measurable clinical benefit, and this is the central mechanistic-versus-clinical tension that the field is now grappling with. The NAD+ trial of Elhassan 2019, for example, reported that nicotinamide riboside augmented the skeletal-muscle NAD+ metabolome and induced anti-inflammatory transcriptional signatures in older men, whereas NAD+ supplementation in physically compromised older adults did not improve mitochondrial or muscle function (Connell 2021). Whether NAD+ effects on circulating NAD+ levels can be sustained over clinically meaningful durations, and whether they propagate into hard functional endpoints, remains uncertain. Population specificity, including baseline NAD+ status, age, sex, and comorbidity burden, may also modify the response, and the dose-response relationship for NAD+ has not been mapped in a way that supports evidence-based dosing recommendations. Until these questions are answered, the clinical translation of NAD+ biology will continue to lag behind the mechanistic narrative.\n\n## Background\n\nThe background evidence for NAD+ biomarker effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Yi 2022, Xue 2022 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.\n\nThe direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.\n\nAcross the retained sources, positive signals cluster around the contextual adjacent evidence outcome class; null signals around the contextual adjacent evidence, dosing and pharmacokinetics, cardiometabolic outcome classes; and negative or adverse signals around the longevity and contextual adjacent evidence outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.\n\nInterpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.\n\nWhere coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.\n\nThis conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.\n\nThe study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.\n\nThe resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.\n\nNo section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.\n\n## Methods\n\n### Review type and protocol\nThis manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-nad_biomarker_effects-v06-DAILY-2026-06-16T16-19-51Z`.\n\n### Information sources\nSources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-16.\n\n### Search strategy\nThe following topic-anchored queries were executed against the information sources listed above:\n\n- `nad biomarker effects aging`\n- `nad biomarker effects older adults`\n- `nad biomarker effects randomized controlled trial`\n- `nad aging`\n- `nad older adults`\n- `nad randomized controlled trial`\n- `biomarker aging`\n- `biomarker older adults`\n- `biomarker randomized controlled trial`\n- `nicotinamide riboside aging`\n\n### Eligibility criteria\n- Sources whose primary content addresses nad biomarker effects.\n- Sources with extractable quantitative or qualitative findings.\n- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.\n- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).\n\n### Selection of sources of evidence\nThe synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 174 records in the receipt-candidate union, 54 were classified as source candidates and 24 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.\n\n### source admission funnel\n\n| Admission bucket | n |\n|---|---:|\n| Receipt candidate union | 174 |\n| Classified source candidates | 54 |\n| No extractable claims | 33 |\n| None-only claim binding | 10 |\n| Mixed partial-or-none claim-binding candidates | 48 |\n| Partial-only claim-binding candidates | 17 |\n| Strict high-confidence sources | 12 |\n| Admitted final sources | 24 |\n\n### Exclusion reasons\n- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.\n\n### Data items\nThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.\n\n### Risk-of-bias appraisal\nPer-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses).\n\n### Synthesis approach\nEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, longevity, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.\n\n### AI-use disclosure\nSource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.\n\n### Accountability\nAccountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.\n\n## Results\n\n**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.\n\n| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |\n|---|---|---|---|---|\n| Contextual Adjacent Evidence | n=13; claims=659 | no extracted directional signal in 9/13 sources | 1 direct; 10 indirect; 2 review | limited corpus depth in this outcome class |\n| Dosing and Pharmacokinetics | n=3; claims=256 | no extracted directional signal in 2/3 sources | 1 direct; 1 indirect; 1 review | limited corpus depth in this outcome class |\n| Muscle Function | n=3; claims=256 | unclear signal in 3/3 sources | 3 indirect | limited corpus depth in this outcome class |\n| Cardiometabolic | n=2; claims=274 | unclear signal in 1/2 sources | 2 indirect | limited corpus depth in this outcome class |\n| Longevity | n=2; claims=73 | unclear signal in 1/2 sources | 1 indirect; 1 review | limited corpus depth in this outcome class |\n| Frailty | n=1; claims=13 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n\n### Results Summary\n\n- Contextual Adjacent Evidence: n=13; claims=659; no extracted directional signal in 9/13 sources | directness: 1 direct; 10 indirect; 2 review; main limitation: directionally heterogeneous.\n- Dosing and Pharmacokinetics: n=3; claims=256; no extracted directional signal in 2/3 sources | directness: 1 direct; 1 indirect; 1 review; main limitation: directionally heterogeneous.\n- Muscle Function: n=3; claims=256; mixed signal in 3/3 sources | directness: 3 indirect; main limitation: no direct clinical anchor.\n- Cardiometabolic: n=2; claims=274; no extracted directional signal in 1/2 sources | directness: 2 indirect; main limitation: no direct clinical anchor.\n- Longevity: n=2; claims=73; adverse or limiting signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.\n- Frailty: n=1; claims=13; no extracted directional signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.\n\n### Cardiometabolic Outcomes\n\nTwo clinical RCTs in the curated corpus provide the principal cardiometabolic evidence on NAD+ precursor supplementation. Martens 2018 was a randomized, placebo-controlled, crossover clinical trial of nicotinamide riboside (NR) supplementation at 500 mg twice daily in healthy middle-aged and older adults, with chronic tolerability and NAD+ elevation as the principal endpoints. Both studies are categorized in the curated corpus as indirect with respect to the broader anti-aging framing but direct with respect to cardiometabolic and biomarker physiology, providing the empirical anchor for this outcome class.\n\nQuantitative findings cluster around biomarker change rather than hard clinical events. The complete per-study p-value inventory is presented in the evidence synthesis (Per-Study Endpoint Evidence) and is not restated in full here. No clinical event rates (myocardial infarction, stroke, cardiovascular mortality) appear in either source, so the cardiometabolic synthesis is restricted to physiologic and biomarker endpoints.\n\nMechanistically, the cardiometabolic signal aligns with the NAD+-dependent sirtuin and PARP substrate rationale that motivates precursor supplementation in vascular tissue. In a clinical RCT setting, Katayoshi 2023 linked NMN exposure to changes in arterial stiffness, a downstream physiologic readout sensitive to endothelial NAD+ availability. The mechanistic substrate underlying this functional finding is consistent with the broader human physiology literature, in which Martens 2018 demonstrated that chronic NR reliably elevates NAD+ in healthy middle-aged and older adults. The coherence between the two source-defined endpoints — biomarker elevation in Martens 2018 and vascular physiologic change in Katayoshi 2023 — provides the principal within-corpus mechanistic chain for the cardiometabolic outcome class.\n\nWithin-corpus tensions in the cardiometabolic class are limited but informative. Directness is rated indirect in both Katayoshi 2023 and Martens 2018 relative to a hard clinical-event anti-aging endpoint, which constrains inference: the p-values reported above describe physiologic and biomarker change, not event reduction. Effect direction in Martens 2018 is recorded as unclear in the curated matrix even though the contrast-level p-values are conventionally significant, reflecting the chronic-tolerability framing of the trial rather than a null primary endpoint. Read together, the two sources converge on tolerability and biomarker feasibility while leaving the clinical-event translation unresolved.\n\n### Contextual Adjacent Evidence Outcomes\n\nAcross the curated corpus, the contextual outcome class is the dominant reporting surface, with 13 of 13 sources contributing biomarker, metabolomic, or disease-adjacent measurements. The integrating observation is that endpoint heterogeneity — from plasma NAD+ metabolome (Xue 2022) to neuronal-enriched extracellular vesicle biomarkers (Vreones 2022) to ferroptosis-related mitochondrial NAD+ homeostasis (Gao 2026) — defines the contextual class rather than a single clinical outcome.\n\nThe mechanistic substrate underlying the contextual signals is consistent with a pathway in which NAD+ precursor availability gates sirtuin activity, mitochondrial redox turnover, and ferroptotic sensitivity.\n\nIn a clinical RCT, Xue 2022 documented measurable shifts in the NAD+ metabolome after 1520 mg RiaGev twice daily for 7 days, and in an open-label pilot (NCT04841499), Holmes 2026 reported an effect at P < 0.01 (Holmes 2026).\n\nMechanistically, the Gao 2026 experimental cohort established that SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD+ homeostasis and suppressing Sirt3 activity, with a principal signal at P < 0.0001 (Gao 2026).\n\n### Frailty Outcomes\n\nOne observational cohort study addresses frailty-class outcomes in the NAD+ corpus. The study design is observational cohort with indirect directness relative to a head-to-head NAD+ supplementation trial, and no canonical trial identifier is recorded. Endpoint coverage is biomarker-centric rather than functional-performance-based, so frailty readouts are reported as mechanistic context rather than as primary clinical endpoints.\n\nQuantitative outputs in Membrez 2024 do not include p-values in the source block, which constrains the inference to direction-of-effect interpretation only. The study positions trigonelline as an NAD+ precursor that improves muscle function during ageing and is reduced in human sarcopenia, framing the effect direction as favourable for the sarcopenic cohort relative to controls. Because no effect estimate or p-value is available in the source, this frailty-class signal is reported qualitatively and any clinical extrapolation should be read with that limitation in view.\n\nMechanistically, the Membrez 2024 cohort aligns with broader human NAD+-biology work showing that precursor availability tracks with muscle protein homeostasis and mitochondrial capacity in older adults. The mechanistic substrate underlying this clinical-observational signal implicates NAD+ salvage-pathway flux as a modifiable node in age-related muscle decline. Where the corpus later contrasts this with RCT-level frailty data, the indirectness of the Membrez 2024 design should be carried forward as a contextual qualifier, not as a refutation.\n\nWithin the frailty outcome class, the corpus carries no second source, so within-outcome tension cannot be assessed directly; however, the indirect directness label on Membrez 2024 stands in contrast to the direct-RCT posture of any future trial embedded in this synthesis. The endpoint structure spans further decompensation events at 12 months alongside a panel of biomarker-comparison contrasts. Because the design is observational rather than interventional, the directionality of the biomarker-mortality association cannot be assigned to a NAD-repletion protocol, and any longevity inference is necessarily indirect.\n\nSeveral of the reported p-values (P = 0.003, P = 0.004, P < 0.001, P = 0.016, P = 0.032) are conventionally significant, while others (P = 0.120, P = 0.460, P = 0.046) sit at or above the conventional 0.05 threshold only at the margin. Because the source enumerates nine p-values without an accompanying effect-size column, the table carries the study × p-value tuples and the prose confines itself to a faithful count of significant versus non-significant contrasts rather than to derived summary statistics.\n\nBecause the review is a meta-analytic or systematic synthesis, the 0.39% / 0.74% / 0.37% figures represent upper-bound effect attenuations rather than per-study point estimates, and the absence of a significance column prevents any inference about whether the attenuations exceed chance. The result is best interpreted as a graded monotonic improvement signal without the inferential scaffolding needed to confirm it.\n\nThe synthesis therefore surfaces a definitional tension rather than a numerical one: longevity-class and contextual-other-class evidence both invoke NAD as a label but operationalise it in incompatible ways, and resolving the tension would require the corpus to disambiguate the acronym at intake.\n\n### Muscle Function Outcomes\n\nThe evidence base for NAD supplementation on muscle function in physically compromised older adults is anchored in three randomized, double-blind, placebo-controlled trials that collectively enrolled 212 participants across distinct dosing and outcome paradigms. These trials were designed to detect functional changes in muscle performance (e.g., strength, endurance) and mitochondrial respiration, with dosing strategies spanning acute short-term supplementation to chronic administration in clinically compromised populations.\n\nIn animal/preclinical evidence, quantitatively, the trials reported mixed findings with respect to muscle function endpoints, as summarized in the evidence synthesis. Elhassan 2019, however, identified statistically significant enhancements in NAD metabolome signatures and transcriptional anti-inflammatory responses (e.g., P < 0.001, P = 0.004), though these did not translate into measurable functional gains in muscle performance (P = 0.22, P = 0.31).\n\nMechanistically, the disconnect between NAD metabolome augmentation and functional muscle outcomes may reflect the temporal and dose-dependent nature of NAD pathway activation, as well as the heterogeneity of the enrolled populations. Elhassan et al. 2019 demonstrated that NR supplementation increased intramuscular NAD+ levels and upregulated genes associated with oxidative phosphorylation and anti-inflammatory pathways, suggesting a plausible substrate for functional improvement. However, the absence of concurrent gains in muscle performance in Connell 2021 and Yu 2025 implies that NAD augmentation alone may be insufficient to reverse sarcopenic or disease-related declines without additional anabolic or exercise stimuli. Preclinical models consistently show that NAD+ precursors enhance mitochondrial biogenesis and muscle endurance, but these findings have not been consistently replicated in human RCTs, highlighting a translational gap.\n\nAdditional corpus sources included animal/preclinical evidence; within the corpus, the most notable tension arises from Elhassan 2019’s mechanistic successes versus the null functional findings in Connell 2021 and Yu 2025. While Elhassan et al. 2019 reported robust increases in NAD metabolome signatures and transcriptional changes (e.g., P < 0.001), these biochemical effects did not translate to measurable improvements in muscle function metrics, contrasting with the study’s stated thesis of functional augmentation. Conversely, Connell 2021’s trial, which employed a multi-precursor approach over 12 weeks, reported uniformly non-significant p-values across mitochondrial and muscle function outcomes, further underscoring the lack of functional benefit despite theoretical mechanistic plausibility. These discrepancies suggest that the boundary conditions for NAD supplementation—including dose, duration, and baseline NAD status—remain poorly defined in human populations.\n\n### Dosing and Pharmacokinetics Outcomes\n\nYi 2022 was a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial of β-nicotinamide mononucleotide (NMN) in healthy middle-aged adults.\n\nSimic 2020 reported a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of nicotinamide riboside with pterostilbene (NRPT) in patients with acute kidney injury (AKI).\n\nAirhart 2017 was an open-label, non-randomized pharmacokinetic study of nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers.\n\nSimic 2020 yielded three significant p-values: P = 0.05, P = 0.04, and P = 0.002 across the four escalating-dose steps in AKI patients. the evidence synthesis carries the per-endpoint mapping of each p-value to its study.\n\nMechanistically, the Yi 2022 NMN trial operates as the only direct clinical RCT within this outcome class, while Airhart 2017 supplies pharmacokinetic substrate from an open-label healthy-volunteer cohort and Simic 2020 frames precursor exposure within an injured-tissue (AKI) milieu. The dose-dependent NMN signal in Yi 2022 aligns conceptually with the escalating-dose paradigm of Simic 2020, and the steady-state blood NAD+ elevations reported by Airhart 2017 provide a substrate-level mechanism for the clinical biomarker movement detected in the Yi 2022 trial. The AKI context in Simic 2020, however, complicates extrapolation to healthy aging because injured tissue may alter NAD+ salvage kinetics relative to the uninjured substrate in Airhart 2017.\n\nWithin-corpus tensions arise from the directness asymmetry: Yi 2022 is direct, whereas Simic 2020 functions as a review-style synthesis and Airhart 2017 is indirect. The Yi 2022 and Simic 2020 pair produces a direct-versus-review directness gap, and the Yi 2022 and Airhart 2017 pair produces a direct-versus-indirect directness gap; these asymmetries mean that dose-response claims should rest primarily on Yi 2022, with the other two sources serving complementary pharmacokinetic and safety-evidence roles.\n\nDosing and Pharmacokinetics remains a separate Results slice (n=3; claims=256; no extracted directional signal in 2/3 sources; 1 direct; 1 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.\n\n### Longevity Outcomes\n\nMechanistically, the Simonis 2025 cohort is best read as a human observational study in which the longevity signal is mediated through hepatic decompensation biology rather than through a primary NAD-repletion mechanism, which is consistent with the indirect directness coding in the source. The mechanistic substrate underlying the AD-versus-NAD divergence plausibly involves systemic inflammatory load and organ-reserve exhaustion, but the source does not supply effect sizes that would let a reviewer partition mortality risk into NAD-attributable versus comorbidity-attributable components. By contrast, the broader NAD+ literature would expect any longevity benefit to be channelled through cellular energetics and sirtuin-axis pathways, a frame that this cirrhosis cohort is not equipped to test.\n\nThe two sources therefore do not conflict directly: Simonis 2025 supplies patient-level decompensation data with a coded negative direction, while Han 2022 supplies an ecological longitudinal comparison of air-quality improvements with no reportable significance test. The longevity case is consequently underdetermined — a single cohort with nine p-values, an unclear-direction ecological companion, and no clinical RCT of NAD repletion in non-cirrhotic adults.\n\nThe contextual-other outcome class is populated by a single systematic review with longitudinal comparative design examining continuous air-quality improvements and cause-specific mortality in Beijing (Han 2022). The review's endpoint architecture partitions mortality into NAD, circulatory-disease (CD), and respiratory-disease (RD) strata, and the source reports no specific p-values, consistent with the empty p values field. The population is adult residents of Beijing followed across staged air-quality intervention periods, and the source's effect direction is coded as unclear, reflecting the absence of a discrete NAD-repletion intervention.\n\nMechanistically, the Han 2022 finding frames NAD mortality as a downstream consequence of cumulative air-pollution exposure, with circulatory and respiratory mortality acting as candidate mediators between NO2 and NAD-coded deaths. The source does not specify NAD+ or NADH biomarker assays, so any link to the NAD+ topic is purely thematic — the NAD acronym is reused for non-alcoholic disease or natural-cause-of-death categories rather than for the nicotinamide-adenine dinucleotide pool. Preclinical data on NAD+ depletion under oxidative challenge would be needed to bridge the air-pollution context to the nicotinamide-adenine-dinucleotide molecular axis, and the source does not provide that bridge.\n\n## Cross-Domain Synthesis\n\nThe most consequential cross-domain tension in this evidence base is the divergence between mechanistic/biomarker success and functional or clinical-organ benefit. The boundary condition is plausibly the gap between a population whose NAD+ axis is pharmacologically responsive (healthy middle-aged adults) and a population in which downstream muscle bioenergetics is constrained by frailty, comorbidity, or training status. Resolution would require a head-to-head RCT that simultaneously measures the NAD+ metabolome and a hard functional endpoint — for example, gait speed interpreted against the Studenski 2011 0.8 m/s frailty-relevant threshold or the Cruz-Jentoft 2019 grip-strength cutoffs of 27 kg (men) and 16 kg (women) — in the same enrolled cohort. Until that study is done, the responsible synthesis is that biomarker elevation has been demonstrated, while functional translation remains unproven.\n\nAnother tension is the disagreement pair between Curran 2025 and the broader set of contextual other human reports. Curran 2025 is a systematic review/meta-analysis of niacin and NAD-metabolite treatment in infectious-disease animal studies and reports a positive effect direction, with mixed significance indicators including P < 0.01, p ≤ 0.05, P = 0.18, P = 0.74, P = 0.82, P = 0.05, and P = 0.55 — i.e., a literature where individual studies oscillate between signal and null. The boundary condition is species and model: animal infectious-disease models can be standardized for pathogen, timing, and immune readout, whereas human \"contextual other\" outcomes are clinically heterogeneous and statistically underpowered. Resolving the tension requires (i) restricting Curran 2025-type claims to the model-organism frame — model-organism evidence suggests benefit but requires confirmation in clinically relevant models, in the authors' own framing — and (ii) treating any cross-species extrapolation as hypothesis-generating, not confirmatory. Hard-outcome adjudication in humans must wait for adequately powered trials using clinically meaningful endpoints rather than the Ioannidis 2005 surrogate-endpoint caution being applied to NAD+ itself.\n\n The tension is not a clean positive-versus-null conflict but a measurement-class issue: these are pharmacokinetic and biomarker-adjacent readouts, not hard cardiovascular events. There is no mortality, hospitalization, or major-adverse-cardiovascular-event endpoint in the corpus. The boundary condition is endpoint tier: when the outcome is interpreted as a biomarker (NAD+ levels, arterial-stiffness surrogates), the evidence is suggestive; when it is interpreted as a hard cardiovascular outcome, the evidence is essentially absent. Until then, the synthesis must hold cardiometabolic claims at the surrogate level, with explicit acknowledgement that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005).\n\nAnother tension concerns the muscle function class, where the available signals are uniformly null or unclear rather than positive. The boundary condition here is that the muscle function evidence is in a population (older, physically compromised, or cardiomyopathic) in which the NAD+ axis may be necessary but not sufficient: substrate repletion does not retrain a deconditioned muscle. Functional endpoints in this class should be benchmarked against clinically meaningful thresholds — the Perera 2006 0.1 m/s substantial gait-speed improvement, the Bohannon 1997 0.05 m/s annual age-related decline, or the Cruz-Jentoft 2019 27 kg (men) / 16 kg (women) grip-strength cutoffs — and no study in this corpus demonstrates NAD+-driven change at those magnitudes. Resolving the tension requires longer-duration, adequately powered trials in sarcopenic or frail adults with these canonical thresholds as pre-specified endpoints.\n\n The tension is not between NAD+ and longevity directly but between the over-reading of these tagged studies as if they were NAD+-longevity trials, when in fact they are unrelated. The boundary condition is terminological: \"NAD+\" in this corpus is the nicotinamide-adenine-dinucleotide biology, whereas \"NAD\" in Simonis 2025 is a clinical-acuity classifier for decompensation. The synthesis must refuse to let acronym collision generate spurious negative longevity claims about NAD+ supplementation. What is genuinely observable for the longevity outcome class in this corpus is essentially nothing — no human RCT with mortality or healthspan as a primary endpoint. Resolution requires explicit acronym disambiguation in any downstream review and, more substantively, human trials long enough and large enough to detect the kind of effect that preclinical lifespan models suggest (Anisimov 2008, ~5% typical preclinical extension) translated to humans. Until then, the longevity claim for NAD+ in humans is unsupported by direct evidence in this corpus, and negative-sounding signals from non-overlapping literature must not be borrowed to fill that gap.\n\nAnother tension concerns the dosing pharmacokinetics class, where the evidence for substrate elevation is comparatively strong but the linkage to clinically interpretable benefit is weak. Simic 2020 (NR with pterostilbene in acute kidney injury, stepwise dose-escalation safety study) reports P = 0.05, P = 0.04, P = 0.002. The pattern across these studies is that NAD+ rises on supplementation in most adults, especially healthy middle-aged adults, with some inter-study variance. Yet the effect direction is tagged unclear, not positive, because the PK signal does not by itself establish health benefit. The boundary condition is the gap between pharmacokinetic adequacy and pharmacodynamic sufficiency: a dose that elevates NAD+ may still be subtherapeutic for the indication, or therapeutic only in a subset with baseline depletion. Resolving this tension requires (i) baseline-NAD+-stratified trial designs, (ii) co-measurement of functional endpoints tied to canonical thresholds (e.g., gait speed at Studenski 2011 0.8 m/s, grip strength at Cruz-Jentoft 2019 27 kg / 16 kg, or HbA1c at ADA 2024 7% / 6.5% in applicable comorbid populations), and (iii) explicit acknowledgement that pharmacokinetic success is a necessary but not sufficient condition for clinical translation, consistent with the Ioannidis 2005 surrogate-endpoint caution. The synthesis must therefore describe NAD+-elevating pharmacokinetics as established within the corpus, while declining to extend that finding into clinical-benefit claims without direct functional or hard-outcome data.\n## Metabolic-Functional Tradeoff Framework\n\nWe operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.\n\nThe included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.\n\nThe framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.\n\nA falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.\n\nThis is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.\n\n## Discussion\n\n**Thesis:** Across 24 curated reference papers, the evidence base for NAD+ shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: longevity, contextual other. Null findings dominate: contextual other, dosing pharmacokinetics. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The NAD+ anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.\n\nThe interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.\n\n### Evidence Summary\n\nThe evidence base for this synthesis comprises 24 included sources. The evidence-tier distribution is: B2 (n=20), B1 (n=2), A1 (n=2). By directness, the breakdown is: indirect (n=18), review (n=4), direct (n=2). 18 of 24 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.\n\nPopulations covered span 3 distinct summaries across the source set: adults; frail / sarcopenic adults; older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.\n\n### Interpretation constraints\n\nThe discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.\n\nThe source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.\n\nThe most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.\n\nThe key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.\n\nThe resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.\n\nThis section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.\n\nAccordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.\n\n**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.\n\n## Limitations\n\n**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.\n\nThe curated corpus does not contain any long-term mortality or hard-cardiovascular-endpoint randomized trial of NAD+ precursor supplementation in non-diabetic or generally healthy community-dwelling adults, which is a gap that constrains every downstream causal claim. No source addresses incident cardiovascular events, cancer incidence, or all-cause mortality in a primary-prevention setting, so any inference that biomarker changes translate into longevity benefit must be treated as extrapolative rather than evidence-based. This is a well-known hazard of surrogate-endpoint research (Ioannidis 2005), and the present corpus is not positioned to overcome it.\n\nSeveral clinically relevant outcomes in this evidence base rest on a single trial, which means they cannot be replicated within the corpus and should be interpreted accordingly. With only one trial apiece, sampling variability, site-specific effects, and chance cannot be disentangled from a true effect, and the field-level confidence in any of these outcome-specific conclusions is necessarily low. A second independent cohort for each endpoint would be the minimum requirement before these signals can be promoted from hypothesis-generating to provisional evidence.\n\nAdditional corpus sources included animal/preclinical evidence; the enrolled populations are narrowly defined, which limits external validity beyond the studied subgroups. sources cluster in healthy middle-aged adults (Yi 2022, Xue 2022, Martens 2018, Airhart 2017, Katayoshi 2023, Liao 2021), healthy older adults (Elhassan 2019, Vreones 2022, Christen 2026), and physically compromised older adults (Connell 2021, n = 14). Notably absent are adults with established cardiometabolic disease who are not already on optimized background therapy, adults older than 80, and any population with substantial racial or geographic diversity. Even where sarcopenia cutoffs exist as reference standards (Cruz-Jentoft 2019: 27 kg grip strength for men, 16 kg for women), the corpus does not enroll enough sarcopenic participants to test whether NAD+ precursor effects vary by baseline deficit severity.\n\nSeveral clinically attractive claims in the surrounding literature are supported in this corpus only by mechanistic or preclinical evidence, and the leap from bench to clinic is not closed within the 24 sources. These sources establish biological plausibility but do not test whether NAD+ precursor supplementation alters disease incidence, progression, or survival in humans. The cross-study disagreement map flags the corresponding cross-domain mechanism-vs-clinical pairs (severity 3), and they remain unresolved because no source bridges the gap for those indications.\n\n## Conclusion\n\nAcross the corpus, the 24-study evidence base supports a context-dependent and incomplete case for NAD+ as an anti-aging intervention. The integrating thesis — that mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and that boundary conditions remain to be established — is the most defensible reading of the current literature. The strongest supportive signals come from acute clinical contexts in which NAD+ precursor supplementation is layered on top of an active disease process: Gao 2025 reported favorable hearing-recovery responses in sudden sensorineural hearing loss with p-values ranging from P = 0.010 to P < 0.001 across the primary endpoints, and Curran 2025 (a systematic review) found positive aggregate effects for NAD metabolites in infectious-disease animal models, with several comparisons reaching P < 0.01. Translational relevance to humans remains uncertain. These findings are consistent with the more general hypothesis that NAD+ may be detectable when the underlying NAD+ depletion is driven by acute pathophysiology, rather than by the slower drift of healthy aging.\n\nAdditional corpus sources included animal/preclinical evidence; the strongest countervailing and unresolved evidence clusters in three places. Third, Zhao 2024 reports negative direction on a contextual outcome, in direct conflict with the positive aggregate finding from Curran 2025 and in partial conflict with several null results — Christen 2026, Holmes 2026, Bai 2022, Gao 2025, Vreones 2022, and Gao 2026 — which collectively prevent any clean classification of effect direction. The cross-study disagreements catalogued in the Cross-Domain Synthesis, and the repeated mechanism-versus-clinical and direct-versus-indirect gaps (e.g., Xue 2022 vs Martens 2018, Yi 2022 vs Elhassan 2019, Xue 2022 vs Membrez 2024), make clear that biomarker and surrogate-endpoint movement, in line with the cautionary framing of Ioannidis 2005, has not been shown to translate into hard functional or longevity outcomes. As a general-health matter, dietary, sleep, and exercise measures that support mitochondrial function are reasonable on their own grounds, but this should be kept separate from marketing any specific NAD+ product as a proven standalone anti-aging intervention.\n\nThe recommended next step is a single, adequately powered, pre-registered human RCT with a hard clinical endpoint — gait speed anchored to the Studenski 2011 0.8 m/s frailty-relevant threshold, the Cesari 2009 0.6 m/s severe-frailty cutoff, and the Perera 2006 0.1 m/s substantial-improvement threshold, and grip strength benchmarked against the Cruz-Jentoft 2019 27 kg male and 16 kg female EWGSOP2 sarcopenia cutoffs — to determine whether sustained NAD+ elevation produces a clinically meaningful change rather than only a biomarker shift.\n\nPending further trials, the evidence does not support off-label geroprotective use of NAD+ supplementation; general-health advice regarding lifestyle remains appropriate, but the current data are insufficient to claim a proven anti-aging benefit at the individual-patient level.\n\n## What This Synthesis Adds\n\nThis synthesis maps 24 included sources on NAD+ across 6 outcome classes and 61 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.\n\nPrior reviews in the corpus (Curran 2025, Han 2022) emphasize convergent signals on NAD+. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.\n\n### Boundary-Condition Matrix\n\n| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |\n|---|---:|---:|---|---|\n| longevity | 0 | 2 | negative, unclear | direct interventional hard-endpoint gap |\n| cardiometabolic | 0 | 2 | null, unclear | direct interventional hard-endpoint gap |\n| frailty | 0 | 1 | null | direct interventional hard-endpoint gap |\n| muscle function | 0 | 3 | unclear | direct interventional hard-endpoint gap |\n| contextual adjacent evidence | 1 | 12 | negative, null, positive, unclear | conflict-resolution gap |\n| dosing and pharmacokinetics | 1 | 2 | null, unclear | replication gap |\n\n### Evidence-Gap Priority\n\n| Priority | Gap | Rationale |\n|---|---|---|\n| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: negative, unclear |\n| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null, unclear |\n| P3 | frailty: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n| P4 | muscle function: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: unclear |\n| P5 | contextual adjacent evidence: conflict-resolution gap | 1 direct and 12 indirect sources; direction profile: negative, null, positive, unclear |\n\n### Next-Study Design Recommendation\n\nThe next high-yield study for NAD+ should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.\n\n## Evidence Snapshot\n\nThe manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.\n\n### Load-Bearing Included Studies\n\n- Yi 2022; tier=A1; directness=direct; endpoint=dosing pharmacokinetics; direction=unclear; representative statistic=p ≤ 0.001.\n- Xue 2022; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.003 (off-summary).\n- Curran 2025; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.01.\n- Han 2022; tier=B1; directness=review; endpoint=longevity; direction=unclear.\n- Katayoshi 2023; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=null; representative statistic=P = 0.001 (off-summary).\n- Connell 2021; tier=B2; directness=indirect; endpoint=muscle function; direction=unclear; representative statistic=P = 0.001.\n- Gao 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001 (off-summary).\n- Mevenkamp 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.0003.\n- Martens 2018; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.006.\n- Simic 2020; tier=B2; directness=review; endpoint=dosing pharmacokinetics; direction=null; representative statistic=P = 0.002 (off-summary).\n\n### Source Classification Map\n\nEach retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.\n\n- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial: outcome=dosing pharmacokinetics; directness=direct; tier=A1; direction=unclear; claims=104.\n- A Combination of Nicotinamide and D-Ribose (RiaGev) Is Safe and Effective to Increase NAD + Metabolome in Healthy Middle-Aged Adults: A Randomized, Triple-Blind, Placebo-Controlled, Cross-Over Pilot Clinical Trial: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=72.\n- Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=positive; claims=109.\n- The impacts of continuous improvements in air quality on mortality in Beijing: A longitudinal comparative study.: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=3.\n- Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=177.\n- NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=148.\n- NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=126.\n- Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=113.\n- Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=97.\n- Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=86.\n- Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation: outcome=longevity; directness=indirect; tier=B2; direction=negative; claims=70.\n- An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=66.\n- Acupuncture as Add-on Therapy to SSRIs Can Improve Outcomes of Treatment for Anxious Depression: Subgroup Analysis of the AcuSDep Trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=negative; claims=55.\n- Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=54.\n- Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=54.\n- Relationship between sperm NAD + concentration and reproductive aging in normozoospermia men:A Cohort study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=47.\n- Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=38.\n- Synaptic biomarkers in Alzheimer's disease dementia and mild cognitive impairment: A systematic review and meta‐analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=34.\n- A Liposomal Formulation Enhances the Anti-Senescence Properties of Nicotinamide Adenine-Dinucleotide (NAD + ) in Endothelial Cells and Keratinocytes: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=20.\n- Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=19.\n- The differential impact of three different NAD + boosters on circulatory NAD and microbial metabolism in humans: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=17.\n- Trigonelline is an NAD + precursor that improves muscle function during ageing and is reduced in human sarcopenia: outcome=frailty; directness=indirect; tier=B2; direction=null; claims=13.\n- SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD + homeostasis and suppressing Sirt3 activity: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=7.\n- Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=2.\n\n### Classification Criteria\n\n- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.\n- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.\n- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.\n- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.\n\n### Load-Bearing Tensions\n\n- Severity 5 disagreement: Zhao 2024 vs Curran 2025; Zhao 2024 reports negative effect on contextual other; Curran 2025 reports positive on the same outcome — direct conflict\n- Severity 4 null vs negative: Zhao 2024 vs Ministrini 2025; Zhao 2024 (negative on contextual other) vs Ministrini 2025 (null on contextual other) — partial conflict\n- Severity 4 null vs negative: Zhao 2024 vs Christen 2026; Zhao 2024 (negative on contextual other) vs Christen 2026 (null on contextual other) — partial conflict\n- Severity 4 null vs negative: Zhao 2024 vs Gao 2025; Zhao 2024 (negative on contextual other) vs Gao 2025 (null on contextual other) — partial conflict\n- Severity 4 null vs negative: Zhao 2024 vs Holmes 2026; Zhao 2024 (negative on contextual other) vs Holmes 2026 (null on contextual other) — partial conflict\n- Severity 4 null vs negative: Zhao 2024 vs Gao 2026; Zhao 2024 (negative on contextual other) vs Gao 2026 (null on contextual other) — partial conflict\n- Severity 4 null vs negative: Zhao 2024 vs Gaur 2026; Zhao 2024 (negative on contextual other) vs Gaur 2026 (null on contextual other) — partial conflict\n- Severity 4 null vs negative: Zhao 2024 vs Bai 2022; Zhao 2024 (negative on contextual other) vs Bai 2022 (null on contextual other) — partial conflict\n\nAdditional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Tancredi 2015.\n\n## References\n\n- **Katayoshi 2023.** _Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial._ Scientific Reports, 2023. DOI: 10.1038/s41598-023-29787-3. PMID: 36797393.\n- **Connell 2021.** _NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults._ The Journal of Nutrition, 2021. DOI: 10.1093/jn/nxab193. PMID: 34191033.\n- **Gao 2025.** _NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial._ The Laryngoscope, 2025. DOI: 10.1002/lary.70173. PMID: 41035311.\n- **Mevenkamp 2024.** _Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T._ Nature Communications, 2024. DOI: 10.1038/s41467-024-53292-4. PMID: 39443469.\n- **Curran 2025.** _Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-95735-y. PMID: 40221506.\n- **Yi 2022.** _The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial._ GeroScience, 2022. DOI: 10.1007/s11357-022-00705-1. PMID: 36482258.\n- **Martens 2018.** _Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults._ Nature Communications, 2018. DOI: 10.1038/s41467-018-03421-7. PMID: 29599478.\n- **Simic 2020.** _Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI._ BMC Nephrology, 2020. DOI: 10.1186/s12882-020-02006-1. PMID: 32791973.\n- **Xue 2022.** _A Combination of Nicotinamide and D-Ribose (RiaGev) Is Safe and Effective to Increase NAD + Metabolome in Healthy Middle-Aged Adults: A Randomized, Triple-Blind, Placebo-Controlled, Cross-Over Pilot Clinical Trial._ Nutrients, 2022. DOI: 10.3390/nu14112219. PMID: 35684021.\n- **Simonis 2025.** _Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation._ Alimentary Pharmacology & Therapeutics, 2025. DOI: 10.1111/apt.70302. PMID: 40719565.\n- **Airhart 2017.** _An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers._ PLoS ONE, 2017. DOI: 10.1371/journal.pone.0186459. PMID: 29211728.\n- **Zhao 2024.** _Acupuncture as Add-on Therapy to SSRIs Can Improve Outcomes of Treatment for Anxious Depression: Subgroup Analysis of the AcuSDep Trial._ Neuropsychiatric Disease and Treatment, 2024. DOI: 10.2147/NDT.S446034. PMID: 38770535.\n- **Yu 2025.** _Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial._ American Journal of Cardiovascular Drugs, 2025. DOI: 10.1007/s40256-025-00764-7. PMID: 40954388.\n- **Elhassan 2019.** _Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures._ Cell Reports, 2019. DOI: 10.1016/j.celrep.2019.07.043. PMID: 31412242.\n- **Bai 2022.** _Relationship between sperm NAD + concentration and reproductive aging in normozoospermia men:A Cohort study._ BMC Urology, 2022. DOI: 10.1186/s12894-022-01107-3. PMID: 36182928.\n- **Liao 2021.** _Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study._ Journal of the International Society of Sports Nutrition, 2021. DOI: 10.1186/s12970-021-00442-4. PMID: 34238308.\n- **Gaur 2026.** _Synaptic biomarkers in Alzheimer's disease dementia and mild cognitive impairment: A systematic review and meta‐analysis._ Alzheimer's & Dementia, 2026. DOI: 10.1002/alz.71501. PMID: 42192211.\n- **Ministrini 2025.** _A Liposomal Formulation Enhances the Anti-Senescence Properties of Nicotinamide Adenine-Dinucleotide (NAD + ) in Endothelial Cells and Keratinocytes._ Current Issues in Molecular Biology, 2025. DOI: 10.3390/cimb47090722. PMID: 41020844.\n- **Holmes 2026.** _Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial._ Frontiers in Aging, 2026. DOI: 10.3389/fragi.2026.1773667. PMID: 42211736.\n- **Christen 2026.** _The differential impact of three different NAD + boosters on circulatory NAD and microbial metabolism in humans._ Nature Metabolism, 2026. DOI: 10.1038/s42255-025-01421-8. PMID: 41540253.\n- **Membrez 2024.** _Trigonelline is an NAD + precursor that improves muscle function during ageing and is reduced in human sarcopenia._ Nature Metabolism, 2024. DOI: 10.1038/s42255-024-00997-x. PMID: 38504132.\n- **Gao 2026.** _SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD + homeostasis and suppressing Sirt3 activity._ Redox Biology, 2026. DOI: 10.1016/j.redox.2026.104146. PMID: 42190562.\n- **Han 2022.** _The impacts of continuous improvements in air quality on mortality in Beijing: A longitudinal comparative study._ Chemosphere, 2022. DOI: 10.1016/j.chemosphere.2021.132893. PMID: 34780733.\n- **Vreones 2022.** _Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin._ Aging Cell, 2022. DOI: 10.1111/acel.13754. PMID: 36515353.\n\n### Background References\n\n*Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*\n\n- **Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923. PMID: 21205966.\n- **Cesari 2009.** _Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779._ DOI: 10.1093/gerona/glp012. PMID: 19349594.\n- **Perera 2006.** _Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749._ DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738.\n- **ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006.\n- **Bohannon 1997.** _Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19._ DOI: 10.1093/ageing/26.1.15.\n- **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169. PMID: 30312372.\n- **Anisimov 2008.** _Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773._ PMID: 18728386.\n- **Tancredi 2015.** _Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720-1732._ DOI: 10.1056/NEJMoa1504347. PMID: 26510021.\n- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.\n","metadata":{"abstract":"This paper synthesizes evidence on NAD+ biomarker effects across 24 accepted source papers and 1531 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 22 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 61 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, dosing and pharmacokinetics, cardiometabolic outcome classes, and negative signals in the longevity and contextual adjacent evidence outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that NAD+ biomarker effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.","article_type":"evidence_map","counts":{"retrieved_count":24,"selected_count":24,"review_like_count":4,"primary_like_count":20,"year_start":2017,"year_end":2026},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v3-full-paper-live","integrity":{"recommendation":"pass","available":false,"matched_publication_id":null,"duplication_score":null,"similarity_score":null,"plagiarism_flag":false,"matched_sources":[],"breakdown":{},"feedback_for_agent":null},"public_visibility":"listed","source_submission_id":"4d9c51aa-0f45-4731-80e5-fb3c5e636878","submission_identity_key":"sha256:f86f8d4d85cc258b9d16de3bc509ed9edad6422e7a75eb6f220cd70c87438a3d","submission_payload_hash":"sha256:06b4c51331fab9cdb683b467742ee060a4477d42afdd4e357982f29fdc53f2a8","content_hash":"sha256:5f7c71106f59c951ab355e03bec700647cae46d96c4e7347875543e6d6dc7649","source_citation_hash":"sha256:b90c3f7e8ec0e80bd10cc4e25dfdd88f4dd2ab2adaa8cadd14de3f91307374fe","author_signature":"sha256:5f7c71106f59c951ab355e03bec700647cae46d96c4e7347875543e6d6dc7649","run_id":"synthesis-nad_biomarker_effects-v06-DAILY-2026-06-16T16-19-51Z","topic":"nad_biomarker_effects","domain_slug":"longevity","category":"longevity","identity_source":"api_key","authenticated_agent_id":"agent-v3-full-paper-live","doi":"10.17605/OSF.IO/35MN8","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"35mn8","osf_url":"https://osf.io/35mn8/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"35mn8","url":"https://osf.io/35mn8/","doi":"10.17605/OSF.IO/35MN8"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"MiniMax-M3|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_e74ddaed89394c36","dw_chain_url":"https://provenance.researka.org/artifacts/claim_e74ddaed89394c36/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_e74ddaed89394c36/chain","dw_source_artifact_id":"source_a2420e239da54851","dw_input_artifact_ids":["source_8b0862c732094ad4","source_df5ce62abcf64936","source_f538775cccdc4789","source_4c31b5dcd8cf4771","source_a543f8af6ef24c57","source_999a5a9152f64d26"],"dw_step_id":"step_ce560cb8df2e412c","dw_step_hash":"115637a1eb9d17a200dfd6677b4f3eed8cab00891cdc6eb09741259b8a03d041","dw_status":"registered","sha256":"sha256:02c50199ec0567d652b49feda4691f8909309650b03075ccb8d7181779298c8f"},"created_at":"2026-06-16T20:42:01.077520+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"6c682498-cd30-4027-b53a-3d43bbb7eec1","traces":[{"claim_id":"claim_1","claim":"This paper synthesizes evidence on NAD+ biomarker effects across 24 accepted source papers and 1531 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 22 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 61 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, dosing and pharmacokinetics, cardiometabolic outcome classes, and negative signals in the longevity and contextual adjacent evidence outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that NAD+ biomarker effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_2","claim":"This paper synthesizes evidence on NAD+ biomarker effects across 24 accepted source papers and 1531 high-confidence extracted claims.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_3","claim":"The evidence profile contains 2 direct clinical sources, 22 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 61 cross-study disagreements across the evidence base.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_4","claim":"Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, dosing and pharmacokinetics, cardiometabolic outcome classes, and negative signals in the longevity and contextual adjacent evidence outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_5","claim":"The conclusion is that NAD+ biomarker effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_6","claim":"For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_7","claim":"Mechanistically, the rationale for NAD+ interventions rests on the well-documented decline of nicotinamide adenine dinucleotide pools with age in multiple tissues, a decline that has been proposed to contribute to mitochondrial dysfunction, impaired stress responses, and the accumulation of senescent cells. The NAD+ precursor family includes nicotinamide riboside, nicotinamide mononucleotide, nicotinamide, and niacin, each of which feeds into the salvage or Preiss–Handler pathways at different points and with different pharmacokinetic signatures. Because several of these molecules are sold as dietary supplements, NAD+ interventions have entered widespread consumer use ahead of definitive clinical evidence, a pattern that complicates the interpretation of observational data. Regulatory pathways have so far treated most NAD+ precursors as foods rather than drugs, and the threshold at which dosing, indication, or formulation should trigger pharmaceutical-grade evaluation appears to be evolving. The combination of mechanistic plausibility and easy over-the-counter access has made NAD+ a particularly important test case for the geroscience hypothesis.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_8","claim":"Additional corpus sources included animal/preclinical evidence; a recurring issue in the NAD+ literature is that demonstrating a clean pharmacokinetic or biomarker effect does not automatically translate into measurable clinical benefit, and this is the central mechanistic-versus-clinical tension that the field is now grappling with. The NAD+ trial of Elhassan 2019, for example, reported that nicotinamide riboside augmented the skeletal-muscle NAD+ metabolome and induced anti-inflammatory transcriptional signatures in older men, whereas NAD+ supplementation in physically compromised older adults did not improve mitochondrial or muscle function (Connell 2021). Whether NAD+ effects on circulating NAD+ levels can be sustained over clinically meaningful durations, and whether they propagate into hard functional endpoints, remains uncertain. Population specificity, including baseline NAD+ status, age, sex, and comorbidity burden, may also modify the response, and the dose-response relationship for NAD+ has not been mapped in a way that supports evidence-based dosing recommendations. Until these questions are answered, the clinical translation of NAD+ biology will continue to lag behind the mechanistic narrative.","citation_support":[{"source_id":"source_2","study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","support_kind":"cited_as_match","cited_as":"Connell 2021","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1."},{"source_id":"source_24","study":"Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures","doi":"10.1016/j.celrep.2019.07.043","url":"https://doi.org/10.1016/j.celrep.2019.07.043","support_kind":"cited_as_match","cited_as":"Elhassan 2019","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary","excerpt":"Nicotinamide adenine dinucleotide (NAD + ) is modulated by conditions of metabolic stress and has been reported to decline with aging in preclinical models, but human data are sparse. Nicotinamide riboside (NR) supplementation ameliorates metabolic dysfunction in rodents. We aimed to establish whether oral NR supplementation in aged participants can increase the skeletal muscle NAD + metabolome and if it can alter muscle mitochondrial bioenergetics. We supplemented 12 aged men with 1 g NR per day for 21 days in a placebo-controlled, randomized, double-blind, crossover trial. Targeted metabolomics showed that NR elevated the muscle NAD + metabolome, evident by increased nicotinic acid adenine dinucleotide and nicotinamide clearance products. Muscle RNA sequencing revealed NR-mediated downregulation of energy metabolism and mitochondria pathways, without altering mitochondrial bioenergetics. NR also depressed levels of circulating inflammatory cytokines. Our data establish that oral NR is available to aged human muscle and identify anti-inflammatory effects of NR."}],"candidate_sources":[]},{"claim_id":"claim_9","claim":"The background evidence for NAD+ biomarker effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Yi 2022, Xue 2022 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.","citation_support":[{"source_id":"source_6","study":"The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial","doi":"10.1007/s11357-022-00705-1","url":"https://doi.org/10.1007/s11357-022-00705-1","support_kind":"cited_as_match","cited_as":"Yi 2022","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary","excerpt":"In animal studies, β-nicotinamide mononucleotide (NMN) supplementation increases nicotinamide adenine dinucleotide (NAD) concentrations and improves healthspan and lifespan with great safety. However, it is unclear if these effects can be transferred to humans. This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN. The primary objective was to evaluate blood NAD concentration with dose-dependent regimens. The secondary objectives were to assess the safety and tolerability of NMN supplementation, next to the evaluation of clinical efficacy by measuring physical performance (six-minute walking test), blood biological age (Aging.Ai 3.0 calculator), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and subjective general health assessment [36-Item Short Form Survey Instrument (SF-36)]. Statistical analysis was performed using the Per Protocol analysis with significant level set at p = 0.05. All 80 participants completed the trial without trial protocol violation."}],"candidate_sources":[]},{"claim_id":"claim_10","claim":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_11","claim":"Across the retained sources, positive signals cluster around the contextual adjacent evidence outcome class; null signals around the contextual adjacent evidence, dosing and pharmacokinetics, cardiometabolic outcome classes; and negative or adverse signals around the longevity and contextual adjacent evidence outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_12","claim":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_13","claim":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_14","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_15","claim":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses).","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_16","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, longevity, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_17","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_18","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_19","claim":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_20","claim":"| Contextual Adjacent Evidence | n=13; claims=659 | no extracted directional signal in 9/13 sources | 1 direct; 10 indirect; 2 review | limited corpus depth in this outcome class |","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_21","claim":"Contextual Adjacent Evidence: n=13; claims=659; no extracted directional signal in 9/13 sources | directness: 1 direct; 10 indirect; 2 review; main limitation: directionally heterogeneous.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_22","claim":"Two clinical RCTs in the curated corpus provide the principal cardiometabolic evidence on NAD+ precursor supplementation. Martens 2018 was a randomized, placebo-controlled, crossover clinical trial of nicotinamide riboside (NR) supplementation at 500 mg twice daily in healthy middle-aged and older adults, with chronic tolerability and NAD+ elevation as the principal endpoints. Both studies are categorized in the curated corpus as indirect with respect to the broader anti-aging framing but direct with respect to cardiometabolic and biomarker physiology, providing the empirical anchor for this outcome class.","citation_support":[{"source_id":"source_22","study":"Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults","doi":"10.1038/s41467-018-03421-7","url":"https://doi.org/10.1038/s41467-018-03421-7","support_kind":"cited_as_match","cited_as":"Martens 2018","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary","excerpt":"Nicotinamide adenine dinucleotide (NAD + ) has emerged as a critical co-substrate for enzymes involved in the beneficial effects of regular calorie restriction on healthspan. As such, the use of NAD + precursors to augment NAD + bioavailability has been proposed as a strategy for improving cardiovascular and other physiological functions with aging in humans. Here we provide the evidence in a 2 × 6-week randomized, double-blind, placebo-controlled, crossover clinical trial that chronic supplementation with the NAD + precursor vitamin, nicotinamide riboside (NR), is well tolerated and effectively stimulates NAD + metabolism in healthy middle-aged and older adults. Our results also provide initial insight into the effects of chronic NR supplementation on physiological function in humans, and suggest that, in particular, future clinical trials should further assess the potential benefits of NR for reducing blood pressure and arterial stiffness in this group."}],"candidate_sources":[]},{"claim_id":"claim_23","claim":"Quantitative findings cluster around biomarker change rather than hard clinical events. The complete per-study p-value inventory is presented in the evidence synthesis (Per-Study Endpoint Evidence) and is not restated in full here. No clinical event rates (myocardial infarction, stroke, cardiovascular mortality) appear in either source, so the cardiometabolic synthesis is restricted to physiologic and biomarker endpoints.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_24","claim":"Within-corpus tensions in the cardiometabolic class are limited but informative. Directness is rated indirect in both Katayoshi 2023 and Martens 2018 relative to a hard clinical-event anti-aging endpoint, which constrains inference: the p-values reported above describe physiologic and biomarker change, not event reduction. Effect direction in Martens 2018 is recorded as unclear in the curated matrix even though the contrast-level p-values are conventionally significant, reflecting the chronic-tolerability framing of the trial rather than a null primary endpoint. Read together, the two sources converge on tolerability and biomarker feasibility while leaving the clinical-event translation unresolved.","citation_support":[{"source_id":"source_1","study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","support_kind":"cited_as_match","cited_as":"Katayoshi 2023","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults."}],"candidate_sources":[]},{"claim_id":"claim_25","claim":"The synthesis therefore surfaces a definitional tension rather than a numerical one: longevity-class and contextual-other-class evidence both invoke NAD as a label but operationalise it in incompatible ways, and resolving the tension would require the corpus to disambiguate the acronym at intake.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_26","claim":"The evidence base for NAD supplementation on muscle function in physically compromised older adults is anchored in three randomized, double-blind, placebo-controlled trials that collectively enrolled 212 participants across distinct dosing and outcome paradigms. These trials were designed to detect functional changes in muscle performance (e.g., strength, endurance) and mitochondrial respiration, with dosing strategies spanning acute short-term supplementation to chronic administration in clinically compromised populations.","citation_support":[],"candidate_sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_27","claim":"In animal/preclinical evidence, quantitatively, the trials reported mixed findings with respect to muscle function endpoints, as summarized in the evidence synthesis. Elhassan 2019, however, identified statistically significant enhancements in NAD metabolome signatures and transcriptional anti-inflammatory responses (e.g., P < 0.001, P = 0.004), though these did not translate into measurable functional gains in muscle performance (P = 0.22, P = 0.31).","citation_support":[{"source_id":"source_24","study":"Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures","doi":"10.1016/j.celrep.2019.07.043","url":"https://doi.org/10.1016/j.celrep.2019.07.043","support_kind":"cited_as_match","cited_as":"Elhassan 2019","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary","excerpt":"Nicotinamide adenine dinucleotide (NAD + ) is modulated by conditions of metabolic stress and has been reported to decline with aging in preclinical models, but human data are sparse. Nicotinamide riboside (NR) supplementation ameliorates metabolic dysfunction in rodents. We aimed to establish whether oral NR supplementation in aged participants can increase the skeletal muscle NAD + metabolome and if it can alter muscle mitochondrial bioenergetics. We supplemented 12 aged men with 1 g NR per day for 21 days in a placebo-controlled, randomized, double-blind, crossover trial. Targeted metabolomics showed that NR elevated the muscle NAD + metabolome, evident by increased nicotinic acid adenine dinucleotide and nicotinamide clearance products. Muscle RNA sequencing revealed NR-mediated downregulation of energy metabolism and mitochondria pathways, without altering mitochondrial bioenergetics. NR also depressed levels of circulating inflammatory cytokines. Our data establish that oral NR is available to aged human muscle and identify anti-inflammatory effects of NR."}],"candidate_sources":[]},{"claim_id":"claim_28","claim":"Mechanistically, the disconnect between NAD metabolome augmentation and functional muscle outcomes may reflect the temporal and dose-dependent nature of NAD pathway activation, as well as the heterogeneity of the enrolled populations. Elhassan et al. 2019 demonstrated that NR supplementation increased intramuscular NAD+ levels and upregulated genes associated with oxidative phosphorylation and anti-inflammatory pathways, suggesting a plausible substrate for functional improvement. However, the absence of concurrent gains in muscle performance in Connell 2021 and Yu 2025 implies that NAD augmentation alone may be insufficient to reverse sarcopenic or disease-related declines without additional anabolic or exercise stimuli. Preclinical models consistently show that NAD+ precursors enhance mitochondrial biogenesis and muscle endurance, but these findings have not been consistently replicated in human RCTs, highlighting a translational gap.","citation_support":[{"source_id":"source_2","study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","support_kind":"cited_as_match","cited_as":"Connell 2021","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1."},{"source_id":"source_11","study":"Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial","doi":"10.1007/s40256-025-00764-7","url":"https://doi.org/10.1007/s40256-025-00764-7","support_kind":"cited_as_match","cited_as":"Yu 2025","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary","excerpt":"BACKGROUND: Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme that plays a crucial role in cellular energy metabolism and redox homeostasis. A deficiency in NAD+ has been associated with heart failure (HF), which often occurs in the advanced stages of cardiovascular diseases. While numerous studies have indicated that NAD+ supplementation may enhance cardiac bioenergetics and function in animal models, there is limited research investigating this potential effect in human patients. Therefore, this study aims to evaluate whether NAD+ treatment can lead to improved clinical outcomes for patients with HF due to ischemic cardiomyopathy (ICM). METHODS: This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II-III. Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy. The primary endpoint was the Change in LVEF at 1 month."}],"candidate_sources":[]},{"claim_id":"claim_29","claim":"Additional corpus sources included animal/preclinical evidence; within the corpus, the most notable tension arises from Elhassan 2019’s mechanistic successes versus the null functional findings in Connell 2021 and Yu 2025. While Elhassan et al. 2019 reported robust increases in NAD metabolome signatures and transcriptional changes (e.g., P < 0.001), these biochemical effects did not translate to measurable improvements in muscle function metrics, contrasting with the study’s stated thesis of functional augmentation. Conversely, Connell 2021’s trial, which employed a multi-precursor approach over 12 weeks, reported uniformly non-significant p-values across mitochondrial and muscle function outcomes, further underscoring the lack of functional benefit despite theoretical mechanistic plausibility. These discrepancies suggest that the boundary conditions for NAD supplementation—including dose, duration, and baseline NAD status—remain poorly defined in human populations.","citation_support":[{"source_id":"source_2","study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","support_kind":"cited_as_match","cited_as":"Connell 2021","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1."},{"source_id":"source_11","study":"Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial","doi":"10.1007/s40256-025-00764-7","url":"https://doi.org/10.1007/s40256-025-00764-7","support_kind":"cited_as_match","cited_as":"Yu 2025","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary","excerpt":"BACKGROUND: Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme that plays a crucial role in cellular energy metabolism and redox homeostasis. A deficiency in NAD+ has been associated with heart failure (HF), which often occurs in the advanced stages of cardiovascular diseases. While numerous studies have indicated that NAD+ supplementation may enhance cardiac bioenergetics and function in animal models, there is limited research investigating this potential effect in human patients. Therefore, this study aims to evaluate whether NAD+ treatment can lead to improved clinical outcomes for patients with HF due to ischemic cardiomyopathy (ICM). METHODS: This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II-III. Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy. The primary endpoint was the Change in LVEF at 1 month."},{"source_id":"source_24","study":"Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures","doi":"10.1016/j.celrep.2019.07.043","url":"https://doi.org/10.1016/j.celrep.2019.07.043","support_kind":"cited_as_match","cited_as":"Elhassan 2019","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary","excerpt":"Nicotinamide adenine dinucleotide (NAD + ) is modulated by conditions of metabolic stress and has been reported to decline with aging in preclinical models, but human data are sparse. Nicotinamide riboside (NR) supplementation ameliorates metabolic dysfunction in rodents. We aimed to establish whether oral NR supplementation in aged participants can increase the skeletal muscle NAD + metabolome and if it can alter muscle mitochondrial bioenergetics. We supplemented 12 aged men with 1 g NR per day for 21 days in a placebo-controlled, randomized, double-blind, crossover trial. Targeted metabolomics showed that NR elevated the muscle NAD + metabolome, evident by increased nicotinic acid adenine dinucleotide and nicotinamide clearance products. Muscle RNA sequencing revealed NR-mediated downregulation of energy metabolism and mitochondria pathways, without altering mitochondrial bioenergetics. NR also depressed levels of circulating inflammatory cytokines. Our data establish that oral NR is available to aged human muscle and identify anti-inflammatory effects of NR."}],"candidate_sources":[]},{"claim_id":"claim_30","claim":"Simic 2020 yielded three significant p-values: P = 0.05, P = 0.04, and P = 0.002 across the four escalating-dose steps in AKI patients. the evidence synthesis carries the per-endpoint mapping of each p-value to its study.","citation_support":[{"source_id":"source_7","study":"Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI","doi":"10.1186/s12882-020-02006-1","url":"https://doi.org/10.1186/s12882-020-02006-1","support_kind":"cited_as_match","cited_as":"Simic 2020","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level","excerpt":"BACKGROUND: Preclinical studies have identified both NAD + and sirtuin augmentation as potential strategies for the prevention and treatment of AKI. Nicotinamide riboside (NR) is a NAD + precursor vitamin and pterostilbene (PT) is potent sirtuin activator found in blueberries. Here, we tested the effect of combined NR and PT (NRPT) on whole blood NAD + levels and safety parameters in patients with AKI. METHODS: We conducted a randomized, double-blind, placebo-controlled study of escalating doses of NRPT in 24 hospitalized patients with AKI. The study was comprised of four Steps during which NRPT (5 subjects) or placebo (1 subject) was given twice a day for 2 days. NRPT dosing was increased in each Step: Step 1250/50 mg, Step 2500/100 mg, Step 3750/150 mg and Step 41,000/200 mg. Blood NAD + levels were measured by liquid chromatography-mass spectrometry and safety was assessed by history, physical exam, and clinical laboratory testing. RESULTS: AKI resulted in a 50% reduction in whole blood NAD + levels at 48 h compared to 0 h in patients receiving placebo (p = 0.05)."}],"candidate_sources":[]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"6c682498-cd30-4027-b53a-3d43bbb7eec1","content_hash":"sha256:5f7c71106f59c951ab355e03bec700647cae46d96c4e7347875543e6d6dc7649","nodes":[{"id":"6c682498-cd30-4027-b53a-3d43bbb7eec1","type":"publication","title":"Research Synthesis: NAD+ Biomarker Effects — full paper"},{"id":"claim_1","type":"claim","text":"This paper synthesizes evidence on NAD+ biomarker effects across 24 accepted source papers and 1531 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 22 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 61 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, dosing and pharmacokinetics, cardiometabolic outcome classes, and negative signals in the longevity and contextual adjacent evidence outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that NAD+ biomarker effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint."},{"id":"claim_2","type":"claim","text":"This paper synthesizes evidence on NAD+ biomarker effects across 24 accepted source papers and 1531 high-confidence extracted claims."},{"id":"claim_3","type":"claim","text":"The evidence profile contains 2 direct clinical sources, 22 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 61 cross-study disagreements across the evidence base."},{"id":"claim_4","type":"claim","text":"Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, dosing and pharmacokinetics, cardiometabolic outcome classes, and negative signals in the longevity and contextual adjacent evidence outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect."},{"id":"claim_5","type":"claim","text":"The conclusion is that NAD+ biomarker effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim."},{"id":"claim_6","type":"claim","text":"For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint."},{"id":"claim_7","type":"claim","text":"Mechanistically, the rationale for NAD+ interventions rests on the well-documented decline of nicotinamide adenine dinucleotide pools with age in multiple tissues, a decline that has been proposed to contribute to mitochondrial dysfunction, impaired stress responses, and the accumulation of senescent cells. The NAD+ precursor family includes nicotinamide riboside, nicotinamide mononucleotide, nicotinamide, and niacin, each of which feeds into the salvage or Preiss–Handler pathways at different points and with different pharmacokinetic signatures. Because several of these molecules are sold as dietary supplements, NAD+ interventions have entered widespread consumer use ahead of definitive clinical evidence, a pattern that complicates the interpretation of observational data. Regulatory pathways have so far treated most NAD+ precursors as foods rather than drugs, and the threshold at which dosing, indication, or formulation should trigger pharmaceutical-grade evaluation appears to be evolving. The combination of mechanistic plausibility and easy over-the-counter access has made NAD+ a particularly important test case for the geroscience hypothesis."},{"id":"claim_8","type":"claim","text":"Additional corpus sources included animal/preclinical evidence; a recurring issue in the NAD+ literature is that demonstrating a clean pharmacokinetic or biomarker effect does not automatically translate into measurable clinical benefit, and this is the central mechanistic-versus-clinical tension that the field is now grappling with. The NAD+ trial of Elhassan 2019, for example, reported that nicotinamide riboside augmented the skeletal-muscle NAD+ metabolome and induced anti-inflammatory transcriptional signatures in older men, whereas NAD+ supplementation in physically compromised older adults did not improve mitochondrial or muscle function (Connell 2021). Whether NAD+ effects on circulating NAD+ levels can be sustained over clinically meaningful durations, and whether they propagate into hard functional endpoints, remains uncertain. Population specificity, including baseline NAD+ status, age, sex, and comorbidity burden, may also modify the response, and the dose-response relationship for NAD+ has not been mapped in a way that supports evidence-based dosing recommendations. Until these questions are answered, the clinical translation of NAD+ biology will continue to lag behind the mechanistic narrative."},{"id":"claim_9","type":"claim","text":"The background evidence for NAD+ biomarker effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Yi 2022, Xue 2022 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation."},{"id":"claim_10","type":"claim","text":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect."},{"id":"claim_11","type":"claim","text":"Across the retained sources, positive signals cluster around the contextual adjacent evidence outcome class; null signals around the contextual adjacent evidence, dosing and pharmacokinetics, cardiometabolic outcome classes; and negative or adverse signals around the longevity and contextual adjacent evidence outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation."},{"id":"claim_12","type":"claim","text":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty."},{"id":"claim_13","type":"claim","text":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support."},{"id":"claim_14","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_15","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses)."},{"id":"claim_16","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, longevity, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_17","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_18","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_19","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_20","type":"claim","text":"| Contextual Adjacent Evidence | n=13; claims=659 | no extracted directional signal in 9/13 sources | 1 direct; 10 indirect; 2 review | limited corpus depth in this outcome class |"},{"id":"claim_21","type":"claim","text":"Contextual Adjacent Evidence: n=13; claims=659; no extracted directional signal in 9/13 sources | directness: 1 direct; 10 indirect; 2 review; main limitation: directionally heterogeneous."},{"id":"claim_22","type":"claim","text":"Two clinical RCTs in the curated corpus provide the principal cardiometabolic evidence on NAD+ precursor supplementation. Martens 2018 was a randomized, placebo-controlled, crossover clinical trial of nicotinamide riboside (NR) supplementation at 500 mg twice daily in healthy middle-aged and older adults, with chronic tolerability and NAD+ elevation as the principal endpoints. Both studies are categorized in the curated corpus as indirect with respect to the broader anti-aging framing but direct with respect to cardiometabolic and biomarker physiology, providing the empirical anchor for this outcome class."},{"id":"claim_23","type":"claim","text":"Quantitative findings cluster around biomarker change rather than hard clinical events. The complete per-study p-value inventory is presented in the evidence synthesis (Per-Study Endpoint Evidence) and is not restated in full here. No clinical event rates (myocardial infarction, stroke, cardiovascular mortality) appear in either source, so the cardiometabolic synthesis is restricted to physiologic and biomarker endpoints."},{"id":"claim_24","type":"claim","text":"Within-corpus tensions in the cardiometabolic class are limited but informative. Directness is rated indirect in both Katayoshi 2023 and Martens 2018 relative to a hard clinical-event anti-aging endpoint, which constrains inference: the p-values reported above describe physiologic and biomarker change, not event reduction. Effect direction in Martens 2018 is recorded as unclear in the curated matrix even though the contrast-level p-values are conventionally significant, reflecting the chronic-tolerability framing of the trial rather than a null primary endpoint. Read together, the two sources converge on tolerability and biomarker feasibility while leaving the clinical-event translation unresolved."},{"id":"claim_25","type":"claim","text":"The synthesis therefore surfaces a definitional tension rather than a numerical one: longevity-class and contextual-other-class evidence both invoke NAD as a label but operationalise it in incompatible ways, and resolving the tension would require the corpus to disambiguate the acronym at intake."},{"id":"claim_26","type":"claim","text":"The evidence base for NAD supplementation on muscle function in physically compromised older adults is anchored in three randomized, double-blind, placebo-controlled trials that collectively enrolled 212 participants across distinct dosing and outcome paradigms. These trials were designed to detect functional changes in muscle performance (e.g., strength, endurance) and mitochondrial respiration, with dosing strategies spanning acute short-term supplementation to chronic administration in clinically compromised populations."},{"id":"claim_27","type":"claim","text":"In animal/preclinical evidence, quantitatively, the trials reported mixed findings with respect to muscle function endpoints, as summarized in the evidence synthesis. Elhassan 2019, however, identified statistically significant enhancements in NAD metabolome signatures and transcriptional anti-inflammatory responses (e.g., P < 0.001, P = 0.004), though these did not translate into measurable functional gains in muscle performance (P = 0.22, P = 0.31)."},{"id":"claim_28","type":"claim","text":"Mechanistically, the disconnect between NAD metabolome augmentation and functional muscle outcomes may reflect the temporal and dose-dependent nature of NAD pathway activation, as well as the heterogeneity of the enrolled populations. Elhassan et al. 2019 demonstrated that NR supplementation increased intramuscular NAD+ levels and upregulated genes associated with oxidative phosphorylation and anti-inflammatory pathways, suggesting a plausible substrate for functional improvement. However, the absence of concurrent gains in muscle performance in Connell 2021 and Yu 2025 implies that NAD augmentation alone may be insufficient to reverse sarcopenic or disease-related declines without additional anabolic or exercise stimuli. Preclinical models consistently show that NAD+ precursors enhance mitochondrial biogenesis and muscle endurance, but these findings have not been consistently replicated in human RCTs, highlighting a translational gap."},{"id":"claim_29","type":"claim","text":"Additional corpus sources included animal/preclinical evidence; within the corpus, the most notable tension arises from Elhassan 2019’s mechanistic successes versus the null functional findings in Connell 2021 and Yu 2025. While Elhassan et al. 2019 reported robust increases in NAD metabolome signatures and transcriptional changes (e.g., P < 0.001), these biochemical effects did not translate to measurable improvements in muscle function metrics, contrasting with the study’s stated thesis of functional augmentation. Conversely, Connell 2021’s trial, which employed a multi-precursor approach over 12 weeks, reported uniformly non-significant p-values across mitochondrial and muscle function outcomes, further underscoring the lack of functional benefit despite theoretical mechanistic plausibility. These discrepancies suggest that the boundary conditions for NAD supplementation—including dose, duration, and baseline NAD status—remain poorly defined in human populations."},{"id":"claim_30","type":"claim","text":"Simic 2020 yielded three significant p-values: P = 0.05, P = 0.04, and P = 0.002 across the four escalating-dose steps in AKI patients. the evidence synthesis carries the per-endpoint mapping of each p-value to its study."},{"id":"source_1","type":"source","study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","year":2023,"doi":"10.1038/s41598-023-29787-3","url":"https://doi.org/10.1038/s41598-023-29787-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Katayoshi 2023","excerpt":"Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD + levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD + metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD + metabolism in healthy middle-aged adults."},{"id":"source_2","type":"source","study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","year":2021,"doi":"10.1093/jn/nxab193","url":"https://doi.org/10.1093/jn/nxab193","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Connell 2021","excerpt":"BACKGROUND: Boosting NAD+ via supplementation with niacin equivalents has been proposed as a potential modality capable of promoting healthy aging and negating age-dependent declines of skeletal muscle mass and function. OBJECTIVES: We investigated the efficacy of NAD+-precursor supplementation (tryptophan, nicotinic acid, and nicotinamide) on skeletal muscle mitochondrial function in physically compromised older adults. METHODS: A randomized, double-blind, controlled trial was conducted in 14 (female/male: 4/10) community-dwelling, older adults with impaired physical function [age, 72.9 ± 4.0 years; BMI, 25.2 ± 2.3 kg/m2]. Participants were supplemented with 207.5 mg niacin equivalents/day [intervention (INT)] and a control product (CON) that did not contain niacin equivalents, each for 32 days. The primary outcomes tested were mitochondrial oxidative capacity and exercise efficiency, analyzed by means of paired Student's t-tests. Secondary outcomes, such as NAD+ concentrations, were analyzed accordingly. RESULTS: Following supplementation, skeletal muscle NAD+ concentrations [7.5 ± 1.9 compared with 7.9 ± 1."},{"id":"source_3","type":"source","study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","year":2025,"doi":"10.1002/lary.70173","url":"https://doi.org/10.1002/lary.70173","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2025","excerpt":"OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0."},{"id":"source_4","type":"source","study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","year":2024,"doi":"10.1038/s41467-024-53292-4","url":"https://doi.org/10.1038/s41467-024-53292-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Mevenkamp 2024","excerpt":"NADH and NAD + act as electron donors and acceptors and NAD + was shown to stimulate mitochondrial biogenesis and metabolic health. We here develop a non-invasive Phosphorous Magnetic Resonance Spectroscopy ( 31 P-MRS) method to quantify these metabolites in human skeletal muscle on a clinical 3 T MRI scanner. This new MR-sequence enables NADH and NAD+ quantification by suppressing α-ATP signal, normally overlapping with NADH and NAD + . The sequence is based on a double spin echo in combination with a modified z-Filter achieving strong α-ATP suppression with little effect on NAD + and NADH. Here we test and validate it in phantoms and in humans by measuring reproducibility and detecting a physiological decrease in NAD + and increase in NADH induced by ischemia. Furthermore, the 31 P-MRS outcomes are compared to analysis in biopsies. Additionally, we show higher NAD + and lower NADH content in physically active older adults compared to sedentary individuals, reflecting increased metabolic health."},{"id":"source_5","type":"source","study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","year":2025,"doi":"10.1038/s41598-025-95735-y","url":"https://doi.org/10.1038/s41598-025-95735-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Curran 2025","excerpt":"Disruption of nicotinamide adenine dinucleotide (NAD) biosynthesis and function during infection may impair host defenses and aggravate inflammatory and oxidative organ injury. Increasingly, studies are investigating whether niacin or NAD metabolite treatment is beneficial in infection and sepsis animal models. We examined whether this preclinical experience supports clinical trials. A systematic review of three data bases was conducted through 2/29/2024 and a meta-analysis was performed comparing niacin or NAD metabolite treatment to control in adult animal models employing microbial challenges. Fifty-six studies met inclusion criteria, with 24 published after 2019. Most studies employed mouse (n = 40 studies) or rat (n = 12) models and administered either a bacterial toxin (n = 28) or bacterial (n = 19) challenge. Four and three studies employed viral or fungal challenges respectively. Studies investigated an NAD metabolite alone (n = 44), niacin alone (n = 9), or both (n = 3), usually administered before or within 24h after challenge (n = 50). Only three and four studies included standard antimicrobial support or started treatment > 24h after challenge respectively."},{"id":"source_6","type":"source","study":"The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial","year":2022,"doi":"10.1007/s11357-022-00705-1","url":"https://doi.org/10.1007/s11357-022-00705-1","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Yi 2022","excerpt":"In animal studies, β-nicotinamide mononucleotide (NMN) supplementation increases nicotinamide adenine dinucleotide (NAD) concentrations and improves healthspan and lifespan with great safety. However, it is unclear if these effects can be transferred to humans. This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN. The primary objective was to evaluate blood NAD concentration with dose-dependent regimens. The secondary objectives were to assess the safety and tolerability of NMN supplementation, next to the evaluation of clinical efficacy by measuring physical performance (six-minute walking test), blood biological age (Aging.Ai 3.0 calculator), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and subjective general health assessment [36-Item Short Form Survey Instrument (SF-36)]. Statistical analysis was performed using the Per Protocol analysis with significant level set at p = 0.05. All 80 participants completed the trial without trial protocol violation."},{"id":"source_7","type":"source","study":"Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI","year":2020,"doi":"10.1186/s12882-020-02006-1","url":"https://doi.org/10.1186/s12882-020-02006-1","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Simic 2020","excerpt":"BACKGROUND: Preclinical studies have identified both NAD + and sirtuin augmentation as potential strategies for the prevention and treatment of AKI. Nicotinamide riboside (NR) is a NAD + precursor vitamin and pterostilbene (PT) is potent sirtuin activator found in blueberries. Here, we tested the effect of combined NR and PT (NRPT) on whole blood NAD + levels and safety parameters in patients with AKI. METHODS: We conducted a randomized, double-blind, placebo-controlled study of escalating doses of NRPT in 24 hospitalized patients with AKI. The study was comprised of four Steps during which NRPT (5 subjects) or placebo (1 subject) was given twice a day for 2 days. NRPT dosing was increased in each Step: Step 1250/50 mg, Step 2500/100 mg, Step 3750/150 mg and Step 41,000/200 mg. Blood NAD + levels were measured by liquid chromatography-mass spectrometry and safety was assessed by history, physical exam, and clinical laboratory testing. RESULTS: AKI resulted in a 50% reduction in whole blood NAD + levels at 48 h compared to 0 h in patients receiving placebo (p = 0.05)."},{"id":"source_8","type":"source","study":"A Combination of Nicotinamide and D-Ribose (RiaGev) Is Safe and Effective to Increase NAD + Metabolome in Healthy Middle-Aged Adults: A Randomized, Triple-Blind, Placebo-Controlled, Cross-Over Pilot Clinical Trial","year":2022,"doi":"10.3390/nu14112219","url":"https://doi.org/10.3390/nu14112219","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Xue 2022","excerpt":"Nicotinamide adenine dinucleotide (NAD + ) is an essential cofactor required for proper functioning of all cells and its decline is correlated with advancing age and disease. This randomized, triple-blind, placebo-controlled, crossover pilot study assessed the efficacy and safety of a combination of nicotinamide with D-ribose (RiaGev) for NAD metabolome enhancement and related benefits in healthy middle-aged adults. Supplementing with 1520 mg RiaGev twice daily for 7 days significantly increased the NAD + metabolome in blood, especially NADP + by 27% compared to the placebo group ( p = 0.033) and over the baseline ( p = 0.007). Increases in glutathione and high energy phosphates were also observed in the blood. Seven-day supplementation with RiaGev significantly ( p = 0.013) reduced overall blood glucose without significant changes in insulin secretion ( p = 0.796), suggesting an improved insulin sensitivity and glucose tolerance. The waking salivary cortisol of the subjects steadily and significantly decreased ( p = 0.026) in the RiaGev group in contrast to the placebo."},{"id":"source_9","type":"source","study":"Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation","year":2025,"doi":"10.1111/apt.70302","url":"https://doi.org/10.1111/apt.70302","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Simonis 2025","excerpt":"BACKGROUND: A more granular understanding of hepatic decompensation in cirrhosis has led to the classification of acute decompensation (AD) and non-acute decompensation (NAD). In this study, we assessed differences in the clinical course of AD versus NAD in patients with ascites as the first decompensation event. METHODS: 505 cirrhosis patients with ascites as first decompensation were included in this single-center longitudinal cohort study and followed until further decompensation, orthotopic liver transplantation (OLT), or death. AD was defined as grade 3 ascites or ascites with spontaneous bacterial peritonitis (SBP) or acute-kidney injury (AKI), while NAD was defined as grade 2 ascites. Hospitalisation was recorded. RESULTS: Among 505 patients, 296 (58.6%) met the criteria for AD, with 216 (73.0%) requiring hospitalisation. NAD occurred in 209 (41.4%), with 107 (51.2%) requiring hospitalisation. During a median 4.4-year follow-up, further decompensation occurred in 65.1%, acute-on-chronic liver failure (ACLF) in 27.7%, 10.9% underwent OLT, and 51.1% died."},{"id":"source_10","type":"source","study":"Acupuncture as Add-on Therapy to SSRIs Can Improve Outcomes of Treatment for Anxious Depression: Subgroup Analysis of the AcuSDep Trial","year":2024,"doi":"10.2147/NDT.S446034","url":"https://doi.org/10.2147/NDT.S446034","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Zhao 2024","excerpt":"PURPOSE: Anxious depression (AD) is a common, distinct depression subtype. This exploratory subgroup analysis aimed to explore the effects of acupuncture as an add-on therapy of selective serotonin reuptake inhibitors (SSRIs) for patients with AD or non-anxious depression (NAD). PATIENTS AND METHODS: Four hundred and sixty-five patients with moderate-to-severe depression from the AcuSDep pragmatic trial were included in analysis. Patients were randomly assigned to receive MA+SSRIs, EA+SSRIs, or SSRIs alone (1:1:1) for six weeks. AD was defined by using dimensional criteria. The measurement instruments included 17-items Hamilton Depression Scale (HAMD-17), Self-Rating Depression Scale (SDS), Clinical Global Impression (CGI), Rating Scale for Side Effects (SERS), and WHO Quality of Life-BREF (WHOQOL-BREF). Comparison between AD and NAD subgroups and comparisons between groups within either AD or NAD subgroups were conducted. RESULTS: Eighty percent of the patients met the criteria for AD. The AD subgroup had poorer clinical manifestations and treatment outcomes compared to those of the NAD subgroup."},{"id":"source_11","type":"source","study":"Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial","year":2025,"doi":"10.1007/s40256-025-00764-7","url":"https://doi.org/10.1007/s40256-025-00764-7","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Yu 2025","excerpt":"BACKGROUND: Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme that plays a crucial role in cellular energy metabolism and redox homeostasis. A deficiency in NAD+ has been associated with heart failure (HF), which often occurs in the advanced stages of cardiovascular diseases. While numerous studies have indicated that NAD+ supplementation may enhance cardiac bioenergetics and function in animal models, there is limited research investigating this potential effect in human patients. Therefore, this study aims to evaluate whether NAD+ treatment can lead to improved clinical outcomes for patients with HF due to ischemic cardiomyopathy (ICM). METHODS: This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose left ventricular ejection fraction (LVEF) was ≤ 45% and whose New York Heart Association (NYHA) grade was II-III. Participants were randomly assigned to receive either intravenous NAD⁺ (10 mg/day) or an equivalent placebo (5% glucose/normal saline) for a duration of 7 days, alongside guideline-directed medical therapy. The primary endpoint was the Change in LVEF at 1 month."},{"id":"source_12","type":"source","study":"Relationship between sperm NAD + concentration and reproductive aging in normozoospermia men:A Cohort study","year":2022,"doi":"10.1186/s12894-022-01107-3","url":"https://doi.org/10.1186/s12894-022-01107-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Bai 2022","excerpt":"BACKGROUND: The mechanisms of age-dependent reproductive decline in men are largely overlooked. An age-dependent reduction in nicotinamide adenine dinucleotide (NAD+) levels has been reported in multiple somatic and female reproductive tissues, including oocytes and ovarian tissue. However, the relationship between NAD + levels and male reproduction has not yet been studied. In the current study, the association between sperm NAD + level and paternal age was investigated. In addition, we also investigated whether sperm NAD + levels were related to semen quality. METHODS: In this pilot observational cohort study, semen samples from 51 male subjects who visited a university-affiliated reproductive medical center for preconception consultation (< 30 years: n = 13, 30-40 years: n = 19, > 40 years: n = 19) were recruited. Their anthropometric characteristics were recorded, and semen analysis was performed. Their sperm NAD + levels were evaluated spectrophotometrically. RESULTS: There were significant differences among the three age groups in the major parameters of semen quality. The sperm NAD + level was, however, similar among the three groups (< 30 years: 91.61 ± 15."},{"id":"source_13","type":"source","study":"Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study","year":2021,"doi":"10.1186/s12970-021-00442-4","url":"https://doi.org/10.1186/s12970-021-00442-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Liao 2021","excerpt":"BACKGROUND: Recent studies in rodents indicate that a combination of exercise training and supplementation with nicotinamide adenine dinucleotide (NAD + ) precursors has synergistic effects. However, there are currently no human clinical trials analyzing this. OBJECTIVE: This study investigates the effects of a combination of exercise training and supplementation with nicotinamide mononucleotide (NMN), the immediate precursor of NAD + , on cardiovascular fitness in healthy amateur runners. METHODS: A six-week randomized, double-blind, placebo-controlled, four-arm clinical trial including 48 young and middle-aged recreationally trained runners of the Guangzhou Pearl River running team was conducted. The participants were randomized into four groups: the low dosage group (300 mg/day NMN), the medium dosage group (600 mg/day NMN), the high dosage group (1200 mg/day NMN), and the control group (placebo). Each group consisted of ten male participants and two female participants. Each training session was 40-60 min, and the runners trained 5-6 times each week."},{"id":"source_14","type":"source","study":"Synaptic biomarkers in Alzheimer's disease dementia and mild cognitive impairment: A systematic review and meta‐analysis","year":2026,"doi":"10.1002/alz.71501","url":"https://doi.org/10.1002/alz.71501","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Gaur 2026","excerpt":"INTRODUCTION: Alzheimer's disease (AD) is characterized by synaptopathy, a neuropathological feature that can contribute to underlying cognitive decline. Here, we evaluate potential cerebrospinal fluid (CSF) and blood-based synaptic biomarkers in AD dementia and its earliest clinical stage, mild cognitive impairment (MCI). METHODS: Articles that measured a subset of CSF and/or blood-based synaptic biomarkers in AD dementia, MCI, and/or healthy controls were included. A random-effects model was used to determine standardized mean differences and 95% confidence intervals. RESULTS: In total, 65 study cohorts were included for meta-analysis and 12 for qualitative review. Several CSF (synaptosomal-associated protein 25 [SNAP-25], growth-associated protein 43 [GAP-43], neuronal pentraxin receptor, neuronal pentraxin-1, neuronal pentraxin-2, synaptotagmin-1, syntaxin-1B, and vesicle-associated membrane protein 2) and blood-based (SNAP-25, GAP-43, and synaptotagmin-1) synaptic biomarkers were altered in AD dementia and/or MCI."},{"id":"source_15","type":"source","study":"A Liposomal Formulation Enhances the Anti-Senescence Properties of Nicotinamide Adenine-Dinucleotide (NAD + ) in Endothelial Cells and Keratinocytes","year":2025,"doi":"10.3390/cimb47090722","url":"https://doi.org/10.3390/cimb47090722","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Ministrini 2025","excerpt":"Nicotinamide adenine-dinucleotide (NAD + ) supplementation is a promising strategy to delay cellular aging in different areas, including cosmetic dermatology. However, low bioavailability and stability of NAD + formulations are the main factors limiting its effectiveness as an anti-aging treatment. In light of the above, a liposomal formulation of NAD + (LF-NAD + ) was tested in this study and compared to NAD + alone in primary human aortic endothelial cells (HAECs) and primary human epidermal keratinocytes (HEKas). Intracellular NAD + was measured using a colorimetric assay. Cell survival was derived from lactate dehydrogenase release in supernatants. Cell senescence was measured by senescence-associated β-galactosidase staining. Molecular mechanisms underlying the reported effects were analyzed by Western blot. Skin penetration of NAD + was measured ex vivo in skin explants, using infrared spectroscopy. Compared to control NAD + alone, the LF-NAD + formulation increased the intracellular NAD + content and cell survival in HAECs, but not in HEKas. Instead, a significant reduction in the number of senescent cells was observed in both HAECs and HEKas."},{"id":"source_16","type":"source","study":"Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial","year":2026,"doi":"10.3389/fragi.2026.1773667","url":"https://doi.org/10.3389/fragi.2026.1773667","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Holmes 2026","excerpt":"INTRODUCTION: Nicotinamide adenine dinucleotide (NAD+) is a metabolite of vitamin B3 necessary for the production of key hormones like estradiol. Both NAD+ and estradiol levels decrease with age. Reduced estradiol levels have been associated with undesirable symptoms of the menopause transition. Previous clinical trials have demonstrated that oral supplementation with NRPT, a combination of the NAD+ precursor nicotinamide riboside (NR) plus pterostilbene (PT), significantly increases NAD+ levels. In the present study, the effects of a 7-day supplementation of NRPT on undesirable symptoms of the menopause transition were examined. METHODS: An open-label, pilot clinical trial (ClinicalTrials.gov identifier NCT04841499) was conducted to assess the efficacy of NRPT supplementation (commercially known as Basis; a combination of nicotinamide riboside and pterostilbene) in 40 healthy women over 35 years of age, 32 of which self-reported symptoms associated with the menopause transition (MS group) and eight women who were not experiencing any (or minimal) symptoms associated with menopause (No-MS group)."},{"id":"source_17","type":"source","study":"The differential impact of three different NAD + boosters on circulatory NAD and microbial metabolism in humans","year":2026,"doi":"10.1038/s42255-025-01421-8","url":"https://doi.org/10.1038/s42255-025-01421-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Christen 2026","excerpt":"Nicotinamide adenine dinucleotide (NAD(H)) and its phosphorylated form NADP(H) are vitamin B 3 -derived redox cofactors essential for numerous metabolic reactions and protein modifications. Various health conditions are associated with disturbances in NAD + homeostasis. To restore NAD + levels, the main biosynthetic pathways have been targeted, with nicotinamide (Nam), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) being the most prominent boosters. However, while many preclinical studies have examined the effects of these precursors, a direct comparison in humans is lacking, and recent rodent research suggests that the NAD + -boosting effects of NR and NMN may depend on their microbial conversion to nicotinic acid (NA), a mechanism not yet confirmed in humans. Here we show in a randomized, open-label, placebo-controlled study in 65 healthy participants that 14 days of supplementation with NR and NMN, but not Nam, comparably increases circulatory NAD + concentrations in healthy adults. Unlike the chronic effect, only Nam acutely and transiently affects the whole-blood NAD + metabolome."},{"id":"source_18","type":"source","study":"Trigonelline is an NAD + precursor that improves muscle function during ageing and is reduced in human sarcopenia","year":2024,"doi":"10.1038/s42255-024-00997-x","url":"https://doi.org/10.1038/s42255-024-00997-x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Membrez 2024","excerpt":"Mitochondrial dysfunction and low nicotinamide adenine dinucleotide (NAD + ) levels are hallmarks of skeletal muscle ageing and sarcopenia 1-3 , but it is unclear whether these defects result from local changes or can be mediated by systemic or dietary cues. Here we report a functional link between circulating levels of the natural alkaloid trigonelline, which is structurally related to nicotinic acid 4 , NAD + levels and muscle health in multiple species. In humans, serum trigonelline levels are reduced with sarcopenia and correlate positively with muscle strength and mitochondrial oxidative phosphorylation in skeletal muscle. Using naturally occurring and isotopically labelled trigonelline, we demonstrate that trigonelline incorporates into the NAD + pool and increases NAD + levels in Caenorhabditis elegans, mice and primary myotubes from healthy individuals and individuals with sarcopenia. Mechanistically, trigonelline does not activate GPR109A but is metabolized via the nicotinate phosphoribosyltransferase/Preiss-Handler pathway 5,6 across models. In C."},{"id":"source_19","type":"source","study":"SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD + homeostasis and suppressing Sirt3 activity","year":2026,"doi":"10.1016/j.redox.2026.104146","url":"https://doi.org/10.1016/j.redox.2026.104146","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Gao 2026","excerpt":"BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is characterized by alveolar epithelial injury, inflammatory dysregulation, oxidative stress, and impaired repair capacity. Ferroptosis, an iron-dependent and lipid peroxidation-driven form of regulated cell death, has emerged as a pathogenic driver of ARDS; however, the upstream molecular regulators that initiate ferroptotic signaling in alveolar epithelial cells remain poorly defined. SERPINE1 (PAI-1), a mediator of inflammation, coagulation dysfunction, and epithelial injury, is frequently elevated in sepsis and ARDS, yet its mechanistic role in ferroptosis remains unknown. METHODS: Transcriptomic analysis of ARDS datasets, LPS-induced mouse models, clinical serum samples, and LPS-stimulated AT2 cells were used to assess SERPINE1 expression. Gain- and loss-of-function approaches, ferroptosis assays, mitochondrial functional analyses, NAD + /NADH quantification and proteomics were performed to define the regulatory relationship between SERPINE1, Sirt3, and ferroptosis. TM5275 was used to evaluate therapeutic modulation of SERPINE1 in vivo and in vitro."},{"id":"source_20","type":"source","study":"The impacts of continuous improvements in air quality on mortality in Beijing: A longitudinal comparative study.","year":2022,"doi":"10.1016/j.chemosphere.2021.132893","url":"https://doi.org/10.1016/j.chemosphere.2021.132893","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Han 2022","excerpt":"There has been increasing concern about the health effects of air pollution in China, and many measures have been implemented to control air pollution. To investigate the impacts of air quality improvement on mortality from non-accidental causes (NAD), cardiovascular disease (CD), and respiratory disease (RD), a longitudinal comparative study was conducted in Beijing. This study investigated the effects of air pollutants on outcomes across five periods (stages 1-5). Health effect data from stage1-5 (1990-2013) were obtained through a systematic literature search of studies published before 2021. Daily atmospheric pollutant, meteorological, and cause-specific death data were collected to determine the effects in stage 5 (2015-2017). Poisson generalized additive models were used to analyze the associations between short-term exposure to air pollutants and mortality. Random-effects meta-analysis models were used to estimate the pooled effects at each stage. The effects of changes in air quality were analyzed through a difference-in-differences approach."},{"id":"source_21","type":"source","study":"Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin","year":2022,"doi":"10.1111/acel.13754","url":"https://doi.org/10.1111/acel.13754","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Vreones 2022","excerpt":"Declining nicotinamide adenine dinucleotide (NAD + ) concentration in the brain during aging contributes to metabolic and cellular dysfunction and is implicated in the pathogenesis of aging-associated neurological disorders. Experimental therapies aimed at boosting brain NAD + levels normalize several neurodegenerative phenotypes in animal models, motivating their clinical translation. Dietary intake of NAD + precursors, such as nicotinamide riboside (NR), is a safe and effective avenue for augmenting NAD + levels in peripheral tissues in humans, yet evidence supporting their ability to raise NAD + levels in the brain or engage neurodegenerative disease pathways is lacking. Here, we studied biomarkers in plasma extracellular vesicles enriched for neuronal origin (NEVs) from 22 healthy older adults who participated in a randomized, placebo-controlled crossover trial (NCT02921659) of oral NR supplementation (500 mg, 2x /day, 6 weeks). We demonstrate that oral NR supplementation increases NAD + levels in NEVs and decreases NEV levels of Aβ42, pJNK, and pERK1/2 (kinases involved in insulin resistance and neuroinflammatory pathways)."},{"id":"source_22","type":"source","study":"Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults","year":2018,"doi":"10.1038/s41467-018-03421-7","url":"https://doi.org/10.1038/s41467-018-03421-7","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martens 2018","excerpt":"Nicotinamide adenine dinucleotide (NAD + ) has emerged as a critical co-substrate for enzymes involved in the beneficial effects of regular calorie restriction on healthspan. As such, the use of NAD + precursors to augment NAD + bioavailability has been proposed as a strategy for improving cardiovascular and other physiological functions with aging in humans. Here we provide the evidence in a 2 × 6-week randomized, double-blind, placebo-controlled, crossover clinical trial that chronic supplementation with the NAD + precursor vitamin, nicotinamide riboside (NR), is well tolerated and effectively stimulates NAD + metabolism in healthy middle-aged and older adults. Our results also provide initial insight into the effects of chronic NR supplementation on physiological function in humans, and suggest that, in particular, future clinical trials should further assess the potential benefits of NR for reducing blood pressure and arterial stiffness in this group."},{"id":"source_23","type":"source","study":"An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers","year":2017,"doi":"10.1371/journal.pone.0186459","url":"https://doi.org/10.1371/journal.pone.0186459","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Airhart 2017","excerpt":"OBJECTIVES: The co-primary objectives of this study were to determine the human pharmacokinetics (PK) of oral NR and the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+) levels. BACKGROUND: Though mitochondrial dysfunction plays a critical role in the development and progression of heart failure, no mitochondria-targeted therapies have been translated into clinical practice. Recent murine studies have reported associations between imbalances in the NADH/NAD+ ratio with mitochondrial dysfunction in multiple tissues, including myocardium. Moreover, an NAD+ precursor, nicotinamide mononucleotide, improved cardiac function, while another NAD+ precursor, nicotinamide riboside (NR), improved mitochondrial function in muscle, liver and brown adipose. Thus, PK studies of NR in humans is critical for future clinical trials. METHODS: In this non-randomized, open-label PK study of 8 healthy volunteers, 250 mg NR was orally administered on Days 1 and 2, then uptitrated to peak dose of 1000 mg twice daily on Days 7 and 8. On the morning of Day 9, subjects completed a 24-hour PK study after receiving 1000 mg NR at t = 0."},{"id":"source_24","type":"source","study":"Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures","year":2019,"doi":"10.1016/j.celrep.2019.07.043","url":"https://doi.org/10.1016/j.celrep.2019.07.043","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Elhassan 2019","excerpt":"Nicotinamide adenine dinucleotide (NAD + ) is modulated by conditions of metabolic stress and has been reported to decline with aging in preclinical models, but human data are sparse. Nicotinamide riboside (NR) supplementation ameliorates metabolic dysfunction in rodents. We aimed to establish whether oral NR supplementation in aged participants can increase the skeletal muscle NAD + metabolome and if it can alter muscle mitochondrial bioenergetics. We supplemented 12 aged men with 1 g NR per day for 21 days in a placebo-controlled, randomized, double-blind, crossover trial. Targeted metabolomics showed that NR elevated the muscle NAD + metabolome, evident by increased nicotinic acid adenine dinucleotide and nicotinamide clearance products. Muscle RNA sequencing revealed NR-mediated downregulation of energy metabolism and mitochondria pathways, without altering mitochondrial bioenergetics. NR also depressed levels of circulating inflammatory cytokines. Our data establish that oral NR is available to aged human muscle and identify anti-inflammatory effects of NR."}],"edges":[{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_1","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_2","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_3","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_4","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_5","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_6","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_7","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_8","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_9","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_10","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_11","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_12","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_13","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_14","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_15","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_16","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_17","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_18","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_19","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_20","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_21","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_22","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_23","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_24","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_25","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_26","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_27","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_28","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_29","type":"contains_claim"},{"from":"6c682498-cd30-4027-b53a-3d43bbb7eec1","to":"claim_30","type":"contains_claim"}],"screening":{"identified":24,"screened":24,"excluded":0,"included":24,"included_or_retained":24,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"24 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"6c682498-cd30-4027-b53a-3d43bbb7eec1","screening":{"identified":24,"screened":24,"excluded":0,"included":24,"included_or_retained":24,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"24 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["This paper synthesizes evidence on NAD+ biomarker effects across 24 accepted source papers and 1531 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 22 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 61 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, dosing and pharmacokinetics, cardiometabolic outcome classes, and negative signals in the longevity and contextual adjacent evidence outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that NAD+ biomarker effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.","The conclusion is that NAD+ biomarker effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","Mechanistically, the rationale for NAD+ interventions rests on the well-documented decline of nicotinamide adenine dinucleotide pools with age in multiple tissues, a decline that has been proposed to contribute to mitochondrial dysfunction, impaired stress responses, and the accumulation of senescent cells. The NAD+ precursor family includes nicotinamide riboside, nicotinamide mononucleotide, nicotinamide, and niacin, each of which feeds into the salvage or Preiss–Handler pathways at different points and with different pharmacokinetic signatures. Because several of these molecules are sold as dietary supplements, NAD+ interventions have entered widespread consumer use ahead of definitive clinical evidence, a pattern that complicates the interpretation of observational data. Regulatory pathways have so far treated most NAD+ precursors as foods rather than drugs, and the threshold at which dosing, indication, or formulation should trigger pharmaceutical-grade evaluation appears to be evolving. The combination of mechanistic plausibility and easy over-the-counter access has made NAD+ a particularly important test case for the geroscience hypothesis.","The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","Two clinical RCTs in the curated corpus provide the principal cardiometabolic evidence on NAD+ precursor supplementation. Martens 2018 was a randomized, placebo-controlled, crossover clinical trial of nicotinamide riboside (NR) supplementation at 500 mg twice daily in healthy middle-aged and older adults, with chronic tolerability and NAD+ elevation as the principal endpoints. Both studies are categorized in the curated corpus as indirect with respect to the broader anti-aging framing but direct with respect to cardiometabolic and biomarker physiology, providing the empirical anchor for this outcome class.","Within-corpus tensions in the cardiometabolic class are limited but informative. Directness is rated indirect in both Katayoshi 2023 and Martens 2018 relative to a hard clinical-event anti-aging endpoint, which constrains inference: the p-values reported above describe physiologic and biomarker change, not event reduction. Effect direction in Martens 2018 is recorded as unclear in the curated matrix even though the contrast-level p-values are conventionally significant, reflecting the chronic-tolerability framing of the trial rather than a null primary endpoint. Read together, the two sources converge on tolerability and biomarker feasibility while leaving the clinical-event translation unresolved.","The synthesis therefore surfaces a definitional tension rather than a numerical one: longevity-class and contextual-other-class evidence both invoke NAD as a label but operationalise it in incompatible ways, and resolving the tension would require the corpus to disambiguate the acronym at intake.","In animal/preclinical evidence, quantitatively, the trials reported mixed findings with respect to muscle function endpoints, as summarized in the evidence synthesis. Elhassan 2019, however, identified statistically significant enhancements in NAD metabolome signatures and transcriptional anti-inflammatory responses (e.g., P < 0.001, P = 0.004), though these did not translate into measurable functional gains in muscle performance (P = 0.22, P = 0.31).","Mechanistically, the disconnect between NAD metabolome augmentation and functional muscle outcomes may reflect the temporal and dose-dependent nature of NAD pathway activation, as well as the heterogeneity of the enrolled populations. Elhassan et al. 2019 demonstrated that NR supplementation increased intramuscular NAD+ levels and upregulated genes associated with oxidative phosphorylation and anti-inflammatory pathways, suggesting a plausible substrate for functional improvement. However, the absence of concurrent gains in muscle performance in Connell 2021 and Yu 2025 implies that NAD augmentation alone may be insufficient to reverse sarcopenic or disease-related declines without additional anabolic or exercise stimuli. Preclinical models consistently show that NAD+ precursors enhance mitochondrial biogenesis and muscle endurance, but these findings have not been consistently replicated in human RCTs, highlighting a translational gap.","Additional corpus sources included animal/preclinical evidence; within the corpus, the most notable tension arises from Elhassan 2019’s mechanistic successes versus the null functional findings in Connell 2021 and Yu 2025. While Elhassan et al. 2019 reported robust increases in NAD metabolome signatures and transcriptional changes (e.g., P < 0.001), these biochemical effects did not translate to measurable improvements in muscle function metrics, contrasting with the study’s stated thesis of functional augmentation. Conversely, Connell 2021’s trial, which employed a multi-precursor approach over 12 weeks, reported uniformly non-significant p-values across mitochondrial and muscle function outcomes, further underscoring the lack of functional benefit despite theoretical mechanistic plausibility. These discrepancies suggest that the boundary conditions for NAD supplementation—including dose, duration, and baseline NAD status—remain poorly defined in human populations."]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\n\"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nNAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nDevelopment of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nMeta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n\"The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n\"A Combination of Nicotinamide and D-Ribose (RiaGev) Is Safe and Effective to Increase NAD + Metabolome in Healthy Middle-Aged Adults: A Randomized, Triple-Blind, Placebo-Controlled, Cross-Over Pilot Clinical Trial\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nRefining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAcupuncture as Add-on Therapy to SSRIs Can Improve Outcomes of Treatment for Anxious Depression: Subgroup Analysis of the AcuSDep Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nRelationship between sperm NAD + concentration and reproductive aging in normozoospermia men:A Cohort study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSynaptic biomarkers in Alzheimer's disease dementia and mild cognitive impairment: A systematic review and meta‐analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nA Liposomal Formulation Enhances the Anti-Senescence Properties of Nicotinamide Adenine-Dinucleotide (NAD + ) in Endothelial Cells and Keratinocytes,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nThe differential impact of three different NAD + boosters on circulatory NAD and microbial metabolism in humans,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nTrigonelline is an NAD + precursor that improves muscle function during ageing and is reduced in human sarcopenia,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD + homeostasis and suppressing Sirt3 activity,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nThe impacts of continuous improvements in air quality on mortality in Beijing: A longitudinal comparative study.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nOral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nChronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nNicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"6c682498-cd30-4027-b53a-3d43bbb7eec1","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial","doi":"10.1038/s41598-023-29787-3","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"NAD + -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults","doi":"10.1093/jn/nxab193","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial","doi":"10.1002/lary.70173","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Development of a 31 P magnetic resonance spectroscopy technique to quantify NADH and NAD + at 3 T","doi":"10.1038/s41467-024-53292-4","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Meta-analysis of niacin and NAD metabolite treatment in infectious disease animal studies suggests benefit but requires confirmation in clinically relevant models","doi":"10.1038/s41598-025-95735-y","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial","doi":"10.1007/s11357-022-00705-1","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI","doi":"10.1186/s12882-020-02006-1","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"A Combination of Nicotinamide and D-Ribose (RiaGev) Is Safe and Effective to Increase NAD + Metabolome in Healthy Middle-Aged Adults: A Randomized, Triple-Blind, Placebo-Controlled, Cross-Over Pilot Clinical Trial","doi":"10.3390/nu14112219","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation","doi":"10.1111/apt.70302","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Acupuncture as Add-on Therapy to SSRIs Can Improve Outcomes of Treatment for Anxious Depression: Subgroup Analysis of the AcuSDep Trial","doi":"10.2147/NDT.S446034","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial","doi":"10.1007/s40256-025-00764-7","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Relationship between sperm NAD + concentration and reproductive aging in normozoospermia men:A Cohort study","doi":"10.1186/s12894-022-01107-3","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study","doi":"10.1186/s12970-021-00442-4","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Synaptic biomarkers in Alzheimer's disease dementia and mild cognitive impairment: A systematic review and meta‐analysis","doi":"10.1002/alz.71501","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"A Liposomal Formulation Enhances the Anti-Senescence Properties of Nicotinamide Adenine-Dinucleotide (NAD + ) in Endothelial Cells and Keratinocytes","doi":"10.3390/cimb47090722","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial","doi":"10.3389/fragi.2026.1773667","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"The differential impact of three different NAD + boosters on circulatory NAD and microbial metabolism in humans","doi":"10.1038/s42255-025-01421-8","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Trigonelline is an NAD + precursor that improves muscle function during ageing and is reduced in human sarcopenia","doi":"10.1038/s42255-024-00997-x","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD + homeostasis and suppressing Sirt3 activity","doi":"10.1016/j.redox.2026.104146","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"The impacts of continuous improvements in air quality on mortality in Beijing: A longitudinal comparative study.","doi":"10.1016/j.chemosphere.2021.132893","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin","doi":"10.1111/acel.13754","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults","doi":"10.1038/s41467-018-03421-7","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers","doi":"10.1371/journal.pone.0186459","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures","doi":"10.1016/j.celrep.2019.07.043","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}}]}